Conference  by unknown
ACC/AHA PRACTICE GUIDELINES
ACC/AHA Guidelines for Implantation of Cardiac Pacemakers and
Antiarrhythmia Devices
A Report of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (Committee on Pacemaker Implantation)
COMMITTEE MEMBERS
GABRIEL GREGORATOS, MD, FACC, Chair
MELVIN D. CHEITLIN, MD, FACC
ALICIA CONILL, MD, FACP*
ANDREW E. EPSTEIN, MD, FACC
CHRISTOPHER FELLOWS, MD, FACC
T. BRUCE FERGUSON, JR., MD, FACC†
ROGER A. FREEDMAN, MD, FACC
MARK A. HLATKY, MD, FACC
GERALD V. NACCARELLI, MD, FACC
SANJEEV SAKSENA, MD, MBBS, FACC‡
ROBERT C. SCHLANT, MD, FACC
MICHAEL J. SILKA, MD, FACC
TASK FORCE MEMBERS
JAMES L. RITCHIE, MD, FACC, Chair
RAYMOND J. GIBBONS, MD, FACC, Vice Chair
MELVIN D. CHEITLIN, MD, FACC
KIM A. EAGLE, MD, FACC
TIMOTHY J. GARDNER, MD, FACC
RICHARD P. LEWIS, MD, FACC
ROBERT A. O’ROURKE, MD, FACC
THOMAS J. RYAN, MD, FACC
ARTHUR GARSON, JR., MD, MPH, FACC
Contents
Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1176
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1177
I. Indications for Permanent Pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1179
A. Pacing for Acquired Atrioventricular Block in Adults . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1179
B. Pacing for Chronic Bifascicular and Trifascicular Block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1180
C. Pacing for Atrioventricular Block Associated With Acute Myocardial Infarction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1181
D. Pacing in Sinus Node Dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1182
E. Prevention and Termination of Tachyarrhythmias by Pacing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1182
*Representative of the American College of Physicians. †Representative of
the Society of Thoracic Surgeons. ‡Representative of the North American
Society of Pacing and Electrophysiology (NASPE). When citing this document,
the American College of Cardiology and the American Heart Association
recommend that the following format be used: Gregoratos G, Cheitlin MD,
Conill A, Epstein AE, Fellows C, Ferguson TB Jr., Freedman RA, Hlatky MA,
Naccarelli GV, Saksena S, Schlant RC, Silka MJ. ACC/AHA guidelines for
implantation of cardiac pacemakers and antiarrhythmia devices: a report of the
American College of Cardiology/American Heart Association Task Force on
Practice Guidelines (Committee on Pacemaker Implantation). J Am Coll Cardiol
1998;31:1175–209.
Address for reprints: A single reprint of this document (the complete Guidelines)
is available by calling 800-253-4636 (US only) or writing the American College of
Cardiology, Educational Services, 9111 Old Georgetown Road, Bethesda, MD
20814–1699. Ask for reprint No. 71-0137. To obtain a reprint of the shorter version
(Executive Summary) published in the April 7, 1998 issue of Circulation, ask for
reprint No. 71-0136. To purchase additional reprints, specify version and reprint
number: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or
more copies, call 214-706-1466, fax 214-691-6342, or E-mail pubauth@amhrt.org.
JACC Vol. 31, No. 5
April 1998:1175–209
1175
©1998 by the American College of Cardiology and the American Heart Association, Inc. 0735-1097/98/$19.00
Published by Elsevier Science Inc. PII S0735-1097(98)00024-2
F. Pacing in Hypersensitive Carotid Sinus and Neurally Mediated Syndromes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1183
G. Pacing in Children and Adolescents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1184
H. Pacing in Specific Conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1186
Hypertrophic Obstructive Cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1186
Idiopathic Dilated Cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1187
Cardiac Transplantation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1187
I. Selection of Pacemaker Device . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1187
Newer Technical Innovations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1188
Methodology of Comparing Different Pacemaker Generators and Configurations . . . . . . . . . . . . . . . . . . . . . . . . . . .1190
Pacing in Sinus Node Dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1191
Pacing in Atrioventricular Block . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1191
Pacing in the Elderly . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1192
Optimizing Pacemaker Technology and Cost . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1192
J. Pacemaker Follow-up. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1192
II. Indications for Implantable Cardioverter-Defibrillator Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1193
A. Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1193
B. Clinical Efficacy of ICD Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1193
C. Alternatives to ICD Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1194
D. Comparison of Drug and Device Therapy for Secondary Prevention of Cardiac Arrest and Sustained Ventricular Tachycardia . . .1194
E. Specific Disease States and Secondary Prevention of Cardiac Arrest or Sustained Ventricular Tachycardia . . . . . . . . . . . . . . .1195
Coronary Artery Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1195
Idiopathic Dilated Cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1195
Long QT Syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1195
Idiopathic Ventricular Fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1195
Hypertrophic Cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1195
Arrhythmogenic Right Ventricular Dysplasia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1196
Syncope With Inducible Sustained Ventricular Tachycardia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1196
F. Pediatric Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1196
G. Primary Prevention of Sudden Cardiac Death . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1196
Coronary Artery Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1196
After Coronary Artery Bypass Surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1197
As a Bridge to Heart Transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1197
Other Populations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1197
H. Contraindications to ICD Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1197
I. Cost-Effectiveness of ICD Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1197
J. Selection of ICD Generators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1197
K. ICD Follow-up Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1198
Elements of ICD Follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1198
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1199
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1207
Preamble
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
and therapies in the management or prevention of disease
states. Rigorous and expert analysis of the available data
documenting relative benefits and risks of those procedures
and therapies can produce helpful guidelines that improve the
effectiveness of care, optimize patient outcomes, and impact
the overall cost of care favorably by focusing resources on the
most effective strategies.
The American College of Cardiology (ACC) and the Amer-
ican Heart Association (AHA) have jointly engaged in the
production of such guidelines in the area of cardiovascular
disease since 1980. This effort is directed by the ACC/AHA
Task Force on Practice Guidelines. Its charge is to develop and
revise practice guidelines for important cardiovascular diseases
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and procedures. Experts in the subject under consideration are
selected from both organizations to examine subject-specific
data and write guidelines. The process includes additional
representatives from other medical practitioner and specialty
groups where appropriate. Writing groups are specifically
charged to perform a formal literature review, weigh the
strength of evidence for or against a particular treatment or
procedure, and include estimates of expected health outcomes
where data exist. Patient-specific modifiers, comorbidities, and
issues of patient preference that might influence the choice of
particular tests or therapies are considered as well as frequency
of follow-up and cost-effectiveness.
These practice guidelines are intended to assist physicians
in clinical decision-making by describing a range of generally
acceptable approaches for the diagnosis, management, or
prevention of specific diseases or conditions. The guidelines
attempt to define practices that meet the needs of most
patients in most circumstances. The ultimate judgment regard-
ing care of a particular patient must be made by the physician
and patient in light of all of the circumstances presented by
that patient.
The Committee on Pacemaker Implantation was chaired by
Gabriel Gregoratos, MD, FACC, and included the following
members: Melvin D. Cheitlin, MD, FACC; Alicia Conill, MD,
FACP; Andrew E. Epstein, MD, FACC; Christopher Fellows,
MD, FACC; T. Bruce Ferguson, Jr., MD, FACC; Roger A.
Freedman, MD, FACC; Mark A. Hlatky, MD, FACC; Gerald
V. Naccarelli, MD, FACC; Sanjeev Saksena, MD, MBBS,
FACC; Robert C. Schlant, MD, FACC; and Michael J. Silka,
MD, FACC. In October 1997, this document was approved for
publication in the Journal of the American College of Cardiology
and the executive summary for publication in Circulation.
The executive summary and recommendations are pub-
lished in the April 7, 1998 issue of Circulation. The full text is
published in the April 1998 issue of the Journal of the American
College of Cardiology. Reprints of both the full text and the
executive summary and recommendations are available from
both organizations.
James L. Ritchie, MD, FACC
Chair, ACC/AHA Task Force on Practice Guidelines
Introduction
This second revision of the “ACC/AHA Guidelines for
Implantation of Cardiac Pacemakers and Antiarrhythmia De-
vices” updates the previous versions published in 1984 and
1991. Revision of the statement was deemed necessary for two
reasons: the publication of major studies that have advanced
our knowledge of the natural history of bradyarrhythmias and
tachyarrhythmias, which may optimally be treated with device
therapy, and major advances in the technology of such devices.
The committee to revise the ACC/AHA Guidelines for
Implantation of Cardiac Pacemakers and Antiarrhythmia De-
vices was composed of both university-affiliated and practicing
physicians. It included experts in the area of device therapy and
follow-up, senior clinicians skilled in cardiovascular care, a
general internist, and a cardiothoracic surgeon. The committee
included representatives of the American College of Physi-
cians, the North American Society of Pacing and Electrophys-
iology (NASPE), and the Society of Thoracic Surgeons. This
document was reviewed by three outside reviewers nominated
by the ACC, three outside reviewers nominated by the AHA,
and individuals representing the American College of Physi-
cians and the North American Society for Pacing and Electro-
physiology. The section “Pacing in Children and Adolescents”
was reviewed by additional reviewers with special expertise in
pediatric electrophysiology. The committee thanks all the
reviewers for their comments. Many of their suggestions were
incorporated into the final document.
The ACC/AHA Guidelines for Implantation of Cardiac
Pacemakers and Antiarrhythmia Devices were approved for
publication by the governing bodies of the ACC and the AHA.
These guidelines will be reviewed 2 years after publication and
yearly thereafter and considered current unless the Task Force
on Practice Guidelines revises or withdraws them from circu-
lation.
The recommendations listed in this document are, when-
ever possible, evidence based. Pertinent medical literature in
the English language was identified through a search of library
databases, and a large number of publications were reviewed
by committee members during the course of their discussions.
Additionally the committee reviewed documents related to the
subject matter previously published by the ACC, the AHA, and
the North American Society for Pacing and Electrophysiology.
References selected and published in this document are rep-
resentative and not all-inclusive.
The committee reviewed and ranked evidence supporting
current recommendations with the weight of evidence ranked
as level A if the data were derived from multiple randomized
clinical trials involving a large number of individuals. The
committee ranked available evidence as level B when data
were derived from a limited number of trials involving a
comparatively small number of patients or from well-designed
data analyses of nonrandomized studies or observational data
registries. Evidence was ranked as level C when the consensus
opinion of experts was the primary source of recommendation.
In the narrative portions of these guidelines, evidence is
generally presented in chronological order of development.
Studies are identified as observational, randomized, prospective,
or retrospective. The committee emphasizes that for certain
conditions for which no other therapy is available, the indica-
tions for device therapy are based on expert consensus and
years of clinical experience and are thus well supported, even
though the evidence was ranked as level C. An analogous
example is the use of penicillin in pneumococcal pneumonia
where there are no randomized trials and only clinical experi-
ence. When indications at level C are supported by historical
clinical data, appropriate references (case reports, clinical
reviews, etc.) are cited if available. When level C indications
are based strictly on committee consensus, no references are
cited. In areas where sparse data were available (eg, pacing in
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children and adolescents), a survey of current practices of
major centers in North America was conducted to determine if
there was a consensus regarding specific pacing indications.
The final recommendations for indications for device ther-
apy are expressed in the standard ACC/AHA format as
follows:
Class I: Conditions for which there is evidence and/or
general agreement that a given procedure or
treatment is beneficial, useful, and effective.
Class II: Conditions for which there is conflicting evidence
and/or a divergence of opinion about the useful-
ness/efficacy of a procedure or treatment.
Class IIa: Weight of evidence/opinion is in favor
of usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well estab-
lished by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that a procedure/treatment is
not useful/effective and in some cases may be
harmful.
The focus of these guidelines is the appropriate use of
devices (pacemakers and implantable cardioverter-defibril-
lators [ICDs]), not the treatment of cardiac arrhythmias. The
fact that use of a device for treatment of a particular condition
is listed as a Class I indication (beneficial, useful, and effective)
does not preclude the use of other therapeutic modalities that
may be equally effective. As with all clinical practice guidelines,
the recommendations in this document focus on treatment of
an average patient with a specific disorder and may be modi-
fied by patient comorbidities, limitation of life expectancy due
to coexisting diseases, and other situations that only the
primary treating physician may evaluate appropriately.
These guidelines include expanded sections on selection of
pacemakers and ICDs, optimization of technology, cost, and
follow-up of implanted devices. The follow-up sections are
relatively brief because in many instances the type and fre-
quency of follow-up examinations are device specific. The
importance of adequate follow-up, however, cannot be over-
emphasized because optimal results from an implanted device
can be obtained only if the device is adjusted to changing
clinical conditions.
The committee considered including a section on extraction
of failed/unused leads, a topic of current interest, but elected
not to do so in the absence of convincing evidence to support
specific criteria for timing and methods of lead extraction. An
upcoming policy statement on lead extraction from the North
American Society of Pacing and Electrophysiology should
provide information on this topic. Similarly, the issue of when
to discontinue long-term cardiac pacing has not been studied
sufficiently to allow formulation of appropriate guidelines
despite the publication of isolated case reports (1). The
committee therefore decided to defer inclusion of this topic
until additional information is available.
The text accompanying the listed indications should be read
carefully because it includes the rationale and supporting
evidence for many of the indications, and in several instances
it includes a discussion of alternative acceptable therapies.
Many of the indications are modified by the term “potentially
reversible.” This term is used to indicate abnormal pathophys-
iology (eg, complete heart block) that may be the result of
reversible factors. Examples include complete heart block due
to drug toxicity (digitalis), electrolyte abnormalities, diseases
with inflammatory peri-atrioventricular node reaction (Lyme
disease), transient injury to the conduction system at the time
of open heart surgery, and others. When faced with a poten-
tially reversible situation, the treating physician must decide
how long a waiting period is justified before beginning device
therapy. The committee recognizes that this statement does
not address issues of length of hospital stay vis a vis managed-
care regulations. It is emphasized that these guidelines are not
intended to address this issue, which falls strictly within the
purview of the treating physician.
The term “symptomatic bradycardia” is used frequently
throughout this document. Symptomatic bradycardia is defined
as a documented bradyarrhythmia that is directly responsible
for development of the clinical manifestations frank syncope or
near-syncope, transient dizziness or light-headedness, and con-
fusional states resulting from cerebral hypoperfusion attribut-
able to slow heart rate. Fatigue, exercise intolerance, and frank
congestive failure may also result from bradycardia. These
symptoms may occur at rest and/or with exertion. Definite
correlation of symptoms with a bradyarrhythmia is required to
fulfill the criteria defining symptomatic bradycardia. Caution
should be exercised not to confuse physiological sinus brady-
cardia (as occurs in highly trained athletes) with pathological
bradyarrhythmias.
In these guidelines the terms “persistent,” “transient,” and
“not expected to resolve” are frequently used. These terms are
not specifically defined because the time element varies in
different clinical conditions. The treating physician must use
appropriate clinical judgment and available data in deciding
when a condition is persistent or when it can be expected to be
transient. Section I.C., “Pacing for Atrioventricular Block
Associated With Acute Myocardial Infarction,” overlaps with
the “ACC/AHA Guidelines for the Management of Patients
With Acute Myocardial Infarction” (2) and includes expanded
indications and stylistic changes. The statement “incidental
finding at electrophysiological study” is used several times in
this document and does not mean that such a study is
indicated. Appropriate indications for electrophysiological
studies have been published (3).
The section on indications for ICDs has been extensively
revised and enlarged to reflect the numerous new develop-
ments in this field and the voluminous literature related to the
efficacy of these devices in the treatment of sudden cardiac
death and malignant ventricular arrhythmias. Indications for
ICDs are continuously changing and can be expected to change
further as ongoing large-scale trials are reported. Thus, the
ICD indications may require revision in the next 2 to 3 years.
In this document the term “mortality” is used to indicate
“all-cause” mortality unless otherwise specified. The commit-
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tee elected to use “all-cause mortality” because of the variable
definition of “sudden death” and the developing consensus to
use all-cause mortality as the most appropriate end point of
clinical trials (4,5).
These guidelines are not designed to specify training or
credentials required for physicians to use device therapy.
Nevertheless, in view of the complexity of both cognitive and
technical aspects of device therapy, only appropriately trained
physicians should use device therapy. Appropriate training
guidelines for physicians have been previously published (6,7).
Finally, because many of the recommended indications are
controversial, the committee urges the sponsoring organiza-
tions to endorse prospective research to address these issues.
I. Indications for Permanent Pacing
A. Pacing for Acquired Atrioventricular Block
in Adults
Atrioventricular (AV) block is classified as first-, second-, or
third-degree (complete) block; anatomically it is defined as
supra-, intra-, or infra-His. First-degree block is defined as
abnormal prolongation of the PR interval. Second-degree AV
block is subclassified as type I (progressive prolongation of PR
interval before a blocked beat) usually associated with a
narrow QRS complex or type II (no progressive prolongation
of PR interval before a blocked beat) usually associated with a
wide QRS complex. Advanced AV block refers to the block of
two or more consecutive P waves. Third-degree AV block
(complete heart block) is defined as absence of AV conduc-
tion.
Patients with abnormalities of AV conduction may be
asymptomatic or may experience serious symptoms related to
bradycardia, ventricular arrhythmias, or both. Decisions re-
garding the need for a pacemaker are importantly influenced
by the presence or absence of symptoms directly attributable to
bradycardia. Furthermore, many of the indications for pacing
have evolved over 30 years based on experience without the
benefit of comparative, randomized clinical trials, in part
because no alternative options exist to treat most bradycardias.
Nonrandomized studies strongly suggest that permanent
pacing does improve survival in patients with third-degree AV
block, especially if syncope has occurred (8–13). Although
there is little evidence to suggest that pacemakers improve
survival in patients with isolated first-degree AV block (14), it
is now recognized that marked first-degree AV block can lead
to symptoms even in the absence of higher degrees of AV
block (15). Such marked first-degree AV block may follow
catheter ablation of the fast pathway with resultant slow
pathway conduction. Marked first-degree AV block for any
reason may also be associated with a pseudopacemaker syn-
drome (16) secondary to close proximity of atrial systole to the
preceding ventricular systole that produces hemodynamic con-
sequences similar to those associated with retrograde (ven-
triculoatrial) conduction. In this instance, atrial contraction
occurs before complete atrial filling, ventricular filling is com-
promised, and an increase in pulmonary capillary wedge
pressure and a decrease in cardiac output follow. Small,
uncontrolled trials have suggested some symptomatic and
functional improvement by pacing of patients with PR intervals
.0.30 second by decreasing the time for AV conduction (15).
Finally, a long PR interval may identify a group of patients with
left ventricular (LV) dysfunction, some of whom may benefit
from dual-chamber pacing with a short(er) AV delay (17).
Consideration should be given to demonstrating hemodynamic
improvement by echocardiographic or invasive assessment
before implantation of a permanent pacemaker.
Progression to advanced AV block in patients with type I
second-degree AV block, when due to delay in the AV node,
is unlikely (18–20), and pacing is usually not indicated. Nev-
ertheless, controversy exists, and pacemaker implantation has
been advocated for this finding (21–23). On the other hand, in
patients with type II second-degree AV block (either intra- or
infra-His), symptoms are frequent, prognosis is compromised,
and progression to third-degree AV block is common
(18,20,24).
Recommendations for permanent pacemaker implantation
in patients with AV block in acute myocardial infarction
(AMI), congenital AV block, and AV block associated with
enhanced vagal tone are discussed in separate sections. Neu-
rally mediated mechanisms in young patients with AV block
should be assessed before proceeding with permanent pacing.
Physiological AV block in the presence of supraventricular
tachyarrhythmias does not constitute an indication for pace-
maker implantation except as specifically defined in the rec-
ommendations that follow. In general, the decision regarding
implantation of a pacemaker must be considered with respect
to whether or not it will be permanent. Reversible causes of
AV block such as electrolyte abnormalities should be corrected
first. Some diseases may follow a natural history to resolution
(eg, Lyme disease), and some AV block can be expected to
reverse (eg, perioperative AV block due to hypothermia or
inflammation near the AV conduction system after surgery for
arrhythmias in this region). Conversely, some conditions may
warrant pacemaker implantation due to anticipated adverse
consequences or disease progression (eg, sarcoid, amyloid)
even if the AV block reverses transiently. Finally, permanent
pacing for AV block after valve surgery follows a variable
natural history, and therefore the decision for permanent
pacing is at the physician’s discretion.
Indications for Permanent Pacing in Acquired
Atrioventricular Block in Adults
Class I
1. Third-degree AV block at any anatomic level, associated
with any one of the following conditions:
a. Bradycardia with symptoms presumed to be due to
AV block. (Level of evidence: C)
b. Arrhythmias and other medical conditions that re-
quire drugs that result in symptomatic bradycardia.
(Level of evidence: C)
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c. Documented periods of asystole >23.0 seconds (25)
or any escape rate <40 beats per minute (bpm) in
awake, symptom-free patients (26,27). (Level of evi-
dence: B, C)
d. After catheter ablation of the AV junction. (Level of
evidence: B, C) There are no trials to assess outcome
without pacing, and pacing is virtually always
planned in this situation unless the operative pro-
cedure is AV junction modification (28,29).
e. Postoperative AV block that is not expected to
resolve. (Level of evidence: C) (30, 30a)
f. Neuromuscular diseases with AV block such as
myotonic muscular dystrophy, Kearns-Sayre syn-
drome, Erb’s dystrophy (limb-girdle), and peroneal
muscular atrophy. (Level of evidence: B) (31–37)
2. Second-degree AV block regardless of type or site of
block, with associated symptomatic bradycardia. (Level
of evidence: B) (19)
Class IIa
1. Asymptomatic third-degree AV block at any anatomic
site with average awake ventricular rates of 40 bpm or
faster. (Level of evidence: B, C)
2. Asymptomatic type II second-degree AV block. (Level of
evidence: B) (21,23)
3. Asymptomatic type I second-degree AV block at intra-
or infra-His levels found incidentally at electrophysio-
logical study performed for other indications. (Level of
evidence: B) (19,21–23)
4. First-degree AV block with symptoms suggestive of
pacemaker syndrome and documented alleviation of
symptoms with temporary AV pacing. (Level of evidence:
B) (15,16)
Class IIb
1. Marked first-degree AV block (>0.30 second) in pa-
tients with LV dysfunction and symptoms of congestive
heart failure in whom a shorter AV interval results in
hemodynamic improvement, presumably by decreasing
left atrial filling pressure. (Level of evidence: C) (17)
Class III
1. Asymptomatic first-degree AV block. (Level of evidence:
B) (14) (See also “Pacing for Chronic Bifascicular and
Trifascicular Block.”)
2. Asymptomatic type I second-degree AV block at the
supra-His (AV node) level or not known to be intra- or
infra-Hisian. (Level of evidence: B, C) (19)
3. AV block expected to resolve and unlikely to recur (38)
(eg, drug toxicity, Lyme disease). (Level of evidence: B)
B. Pacing for Chronic Bifascicular and
Trifascicular Block
Bifascicular and trifascicular block refer to electrocardio-
graphic evidence of impaired conduction below the AV node
in two or three fascicles of the right and left bundles. In
patients with such electrocardiographic abnormalities, there is
convincing evidence that symptomatic, advanced AV block is
associated with a high mortality rate and a significant incidence
of sudden death (9,39).
Syncope is common in patients with bifascicular block.
Usually it is not recurrent or associated with an increased
incidence of sudden death (40–52). It has been suggested that
pacing relieves the transient neurological symptoms but does
not reduce the frequency of sudden death (46). Electrophysi-
ological study may be helpful to evaluate and direct the
treatment of inducible ventricular arrhythmias (53,54) that are
common in patients with bifascicular and trifascicular block.
However, there is also convincing evidence that in the presence
of permanent or transient third-degree AV block, syncope is
associated with an increased incidence of sudden death regard-
less of the results of electrophysiological study (9,54,55). Thus,
if the cause of syncope in the presence of bifascicular or
trifascicular block cannot be determined with certainty or if
treatments used (such as drugs) may exacerbate AV block,
prophylactic permanent pacing is indicated, especially if syn-
cope may have been due to transient third-degree AV block
(40,52).
Although third-degree AV block is most often preceded by
bifascicular block, there is impressive evidence that the rate of
progression of bifascicular block to third-degree AV block is
slow. Furthermore, no single clinical or laboratory variable,
including bifascicular block, identifies patients at high risk of
death from a future bradyarrhythmia due to bundle branch
block (48).
Of the many laboratory variables, the PR and HV intervals
have been identified as possible predictors of third-degree AV
block and sudden death. Evidence indicates that PR interval
prolongation is common in patients with bifascicular block.
However, the prolongation is often at the level of the AV node.
Furthermore, there is no correlation between the PR and HV
intervals or between the length of the PR interval and progres-
sion to third-degree AV block and incidence of sudden death
(43,45,49). Although most patients with chronic or intermittent
third-degree AV block demonstrate prolongation of the HV
interval during anterograde conduction, some investigators
(50,51) have suggested that asymptomatic patients with bifas-
cicular block and a prolonged HV interval should be consid-
ered for permanent pacing, especially if the HV interval is
.2100 milliseconds (49). The evidence indicates that although
the prevalence of prolonged HV is high, the incidence of
progression to third-degree AV block is low. Because HV
prolongation accompanies advanced cardiac disease and is
associated with increased mortality, death is often not sudden
or due to AV block but rather due to the underlying heart
disease itself and nonarrhythmic cardiac causes (43,46 –
49,51,54–56).
Atrial pacing at electrophysiological study in asymptomatic
patients as a means of identifying patients at increased risk of
future high- or third-degree AV block is probably not justified.
The probability of inducing block distal to the AV node (ie,
intra- or infra-His) with rapid atrial pacing is low (47,50,51,57–
60). Furthermore, failure to induce distal block cannot be
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taken as evidence that the patient will not develop third-degree
AV block in the future. However, if atrial pacing induces
nonphysiological infra-His block, some consider this an indi-
cation for pacing (57).
Indications for Permanent Pacing in Chronic
Bifascicular and Trifascicular Block
Class I
1. Intermittent third-degree AV block. (Level of evidence:
B) (8–13,39)
2. Type II second-degree AV block. (Level of evidence: B)
(18,20,24)
Class IIa
1. Syncope not proved to be due to AV block when other
likely causes have been excluded, specifically ventricu-
lar tachycardia (VT). (Level of evidence: B) (40–51,53–
58)
2. Incidental finding at electrophysiological study of
markedly prolonged HV interval (>100 milliseconds) in
asymptomatic patients. (Level of evidence: B) (49)
3. Incidental finding at electrophysiological study of
pacing-induced infra-His block that is not physiologi-




1. Fascicular block without AV block or symptoms. (Level
of evidence: B) (43,45,48,49)
2. Fascicular block with first-degree AV block without
symptoms. (Level of evidence: B) (43,45,48,49)
C. Pacing for Atrioventricular Block Associated
With Acute Myocardial Infarction
Indications for permanent pacing after MI in patients
experiencing AV block are related in large measure to the
presence of intraventricular conduction defects. Unlike some
other indications for permanent pacing, the criteria in patients
with MI and AV block do not necessarily depend on the
presence of symptoms. Furthermore, the requirement for
temporary pacing in AMI does not by itself constitute an
indication for permanent pacing (see ACC/AHA Guidelines
for Management of Patients With Acute Myocardial Infarction
[2]). The long-term prognosis for survivors of AMI who have
had AV block is related primarily to the extent of myocardial
injury and the character of intraventricular conduction distur-
bances rather than the AV block itself (11,61–64). Patients
with AMI who have intraventricular conduction defects, with
the exception of isolated left anterior fascicular block, have an
unfavorable short- and long-term prognosis and an increased
incidence of sudden death (11,24,61,63). This unfavorable
prognosis is not necessarily due to development of high-grade
AV block, although the incidence of such block is higher in
postinfarction patients with abnormal intraventricular conduc-
tion (61,65).
When AV or intraventricular conduction block complicates
AMI, the type of conduction disturbance, location of infarc-
tion, and relation of electrical disturbance to infarction must
be considered as permanent pacing is contemplated. Even with
data available, the decision is not always straightforward,
because the reported incidence and significance of various
conduction disturbances vary widely (66). Despite the use of
thrombolytic therapy, which has decreased the incidence of
AV block in AMI, mortality remains high in this patient group
if AV block occurs (67–70).
Although more severe disturbances in conduction are in
general associated with greater arrhythmic and nonarrhythmic
mortality (61–66), the impact of preexisting bundle branch
block on mortality after AMI is controversial (52,66). How-
ever, a particularly ominous prognosis is associated with left
bundle branch block combined with advanced or third-degree
AV block and with right bundle branch block combined with
left anterior or left posterior fascicular block (41,52,62,64).
Irrespective of whether the infarction is anterior or inferior,
the development of an intraventricular conduction delay re-
flects extensive myocardial damage rather than an electrical
problem in isolation (64). Although AV block that occurs
during inferior MI can be associated with a favorable long-
term clinical outcome, in-hospital survival is impaired, irre-
spective of temporary or permanent pacing in this situation
(67,68,71,72). Furthermore, pacemakers should not be im-
planted if the peri-infarctional AV block is expected to resolve
or not negatively impact long-term prognosis, as in the case of
inferior MI (69).
Indications for Permanent Pacing after the Acute
Phase of Myocardial Infarction*
Class I
1. Persistent second-degree AV block in the His-Purkinje
system with bilateral bundle branch block or third-
degree AV block within or below the His-Purkinje
system after AMI. (Level of evidence: B) (24,61–65)
2. Transient advanced (second- or third-degree) infra-
nodal AV block and associated bundle branch block. If
the site of block is uncertain, an electrophysiological
study may be necessary. (Level of evidence: B) (61,62)
3. Persistent and symptomatic second- or third-degree AV




1. Persistent second- or third-degree AV block at the AV
node level. (Level of evidence: B) (23)
Class III
1. Transient AV block in the absence of intraventricular
conduction defects. (Level of evidence: B) (61)
*These recommendations generally follow the ACC/AHA Guidelines for the
Management of Patients With Acute Myocardial Infarction (2).
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2. Transient AV block in the presence of isolated left
anterior fascicular block. (Level of evidence: B) (63)
3. Acquired left anterior fascicular block in the absence of
AV block. (Level of evidence: B) (61)
4. Persistent first-degree AV block in the presence of
bundle branch block that is old or age indeterminate.
(Level of evidence: B) (61)
D. Pacing in Sinus Node Dysfunction
Sinus node dysfunction (sick sinus syndrome) constitutes a
spectrum of cardiac arrhythmias, including sinus bradycardia,
sinus arrest, sinoatrial block, and paroxysmal supraventricular
tachyarrhythmias alternating with periods of bradycardia or
even asystole. Patients with this condition may be symptomatic
from paroxysmal tachycardia or bradycardia or both. Correla-
tion of symptoms with the above arrhythmias using an electro-
cardiogram (ECG), ambulatory electrocardiographic monitor-
ing, or an event recorder is essential. This correlation may be
difficult because of the intermittent nature of the episodes.
Sinus node dysfunction may express itself as chronotropic
incompetence in which there is an inadequate sinus response
to exercise or stress. Rate-responsive pacemakers have clini-
cally benefited patients by restoring physiological heart rate
during physical activity (73–75).
Sinus bradycardia is accepted as a physiological finding in
trained athletes, who not uncommonly have a heart rate of 40
to 50 bpm while at rest and awake and may have a sleeping rate
as slow as 30 bpm with sinus pauses or type I second-degree
AV block producing asystolic intervals as long as 2.8 seconds
(76–78). These findings are due to increased vagal tone.
Although sinus node dysfunction is frequently the primary
indication for implantation of permanent pacemakers (73),
permanent pacing in patients with sinus node dysfunction may
not necessarily result in improved survival time (26,79), al-
though symptoms related to bradycardia may be relieved
(27,80). Nonrandomized observational studies suggest that
dual-chamber pacing may improve survival compared with
ventricular pacing (81–83). However, one randomized pros-
pective study (84) of 225 patients with sinus node disease and
intact AV nodal conduction followed for a mean of 40 months
demonstrated no difference in overall or cardiac mortality
between the groups receiving atrial versus ventricular pacing.
Multiple small studies suggest that dual-chamber pacing im-
proves quality of life and decreases morbidity (atrial fibrilla-
tion, stroke). Multiple prospective trials are ongoing to assess
the superiority of dual-chamber versus ventricular-based pac-
ing systems in this population (84a).
Indications for Permanent Pacing in Sinus
Node Dysfunction
Class I
1. Sinus node dysfunction with documented symptomatic
bradycardia, including frequent sinus pauses that pro-
duce symptoms. In some patients, bradycardia is iatro-
genic and will occur as a consequence of essential
long-term drug therapy of a type and dose for which
there are no acceptable alternatives. (Level of evidence:
C) (27,73,79)
2. Symptomatic chronotropic incompetence (73–75). (Lev-
el of evidence: C) (27,73,79)
Class IIa
1. Sinus node dysfunction occurring spontaneously or as a
result of necessary drug therapy, with heart rate
<40 bpm when a clear association between significant
symptoms consistent with bradycardia and the actual
presence of bradycardia has not been documented.
(Level of evidence: C) (26,27,73,78–80)
Class IIb
1. In minimally symptomatic patients, chronic heart rate
<30 bpm while awake. (Level of evidence: C)
(26,27,73,78–80)
Class III
1. Sinus node dysfunction in asymptomatic patients, in-
cluding those in whom substantial sinus bradycardia
(heart rate <40 bpm) is a consequence of long-term
drug treatment.
2. Sinus node dysfunction in patients with symptoms
suggestive of bradycardia that are clearly documented
as not associated with a slow heart rate.
3. Sinus node dysfunction with symptomatic bradycardia
due to nonessential drug therapy.
E. Prevention and Termination of
Tachyarrhythmias by Pacing
Under certain circumstances, an implanted pacemaker may
be useful for treating patients with recurrent symptomatic
ventricular and supraventricular tachycardias (85–94). Pacing
can be useful in preventing and terminating arrhythmias.
Reentrant rhythms including atrial flutter, paroxysmal reen-
trant supraventricular tachycardia, and VT may be terminated
by a variety of pacing patterns, including programmed stimu-
lation and short bursts of rapid pacing (95,96). These anti-
tachyarrhythmia devices may detect tachycardia and automat-
ically activate a pacing sequence or they may respond only to
an external instruction, for example, application of a magnet.
Prevention of arrhythmias by pacing has been demonstrated
in certain situations. In some patients with the long QT
syndrome, recurrent pause-dependent VT may be prevented
by continuous pacing (97). A combination of pacing and
b-blockade has been reported to shorten the QT interval and
help prevent sudden cardiac death (98,99).
Atrial synchronous ventricular pacing may prevent recur-
rences of reentrant supraventricular tachycardia (100), al-
though this technique is rarely used, given the availability of
catheter ablation and other alternative therapies. Although
ventricular ectopic activity may be suppressed by such pacing
in other conditions, serious or symptomatic arrhythmias are
rarely prevented (101). In some patients with bradycardia-
dependent atrial fibrillation, atrial pacing may be effective in
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reducing the frequency of recurrence (92). Dual-site right
atrial pacing may offer additional benefits to single-site right
atrial pacing in patients with symptomatic drug-refractory
atrial fibrillation and concomitant bradyarrhythmias (93). In
patients with sick sinus syndrome and intraatrial block (P wave
.180 milliseconds), biatrial pacing may lower recurrence rates
of atrial fibrillation (94).
Potential recipients of antitachyarrhythmia devices that
interrupt arrhythmias should undergo extensive testing before
implantation to ensure that the devices safely and reliably
terminate the ectopic mechanism without accelerating the
tachycardia or inducing ventricular fibrillation (VF). Patients
for whom an antitachycardia pacemaker has been prescribed
have usually been unresponsive to antiarrhythmic drugs or
were receiving agents that could not control their cardiac
arrhythmias. When permanent antitachycardia pacemakers
detect and interrupt supraventricular tachycardia, all pacing
should be done in the atrium because adverse interactions have
been reported (85,102) with use of ventricular pacing to
interrupt supraventricular arrhythmias. Permanent antitachy-
cardia pacing as monotherapy for VT is not appropriate, given
that antitachycardia pacing algorithms are available in tiered-
therapy ICDs that have the capability of cardioversion and
defibrillation in cases when antitachycardia pacing is ineffective
or causes acceleration of the treated tachycardia.
Indications for Permanent Pacemakers That
Automatically Detect and Pace to
Terminate Tachycardias
Class I
1. Symptomatic recurrent supraventricular tachycardia
that is reproducibly terminated by pacing after drugs
and catheter ablation fail to control the arrhythmia or
produce intolerable side effects. (Level of evidence: C)
(86–88,90,91)
2. Symptomatic recurrent sustained VT as part of an





1. Recurrent supraventricular tachycardia or atrial flutter
that is reproducibly terminated by pacing as an alter-
native to drug therapy or ablation. (Level of evidence: C)
(85–88,90,91)
Class III
1. Tachycardias frequently accelerated or converted to
fibrillation by pacing.
2. The presence of accessory pathways with the capacity
for rapid anterograde conduction whether or not the
pathways participate in the mechanism of the tachycar-
dia.
Pacing Indications to Prevent Tachycardia
Class I
1. Sustained pause-dependent VT, with or without pro-
longed QT, in which the efficacy of pacing is thoroughly
documented. (Level of evidence: C) (97,98)
Class IIa
1. High-risk patients with congenital long QT syndrome.
(Level of evidence: C) (97,98)
Class IIb
1. AV reentrant or AV node reentrant supraventricular
tachycardia not responsive to medical or ablative ther-
apy. (Level of evidence: C) (87,88,92)
2. Prevention of symptomatic, drug-refractory, recurrent
atrial fibrillation. (Level of evidence: C) (93,94)
Class III
1. Frequent or complex ventricular ectopic activity with-
out sustained VT in the absence of the long QT syn-
drome.
2. Long QT syndrome due to reversible causes.
F. Pacing in Hypersensitive Carotid Sinus and
Neurally Mediated Syndromes
The hypersensitive carotid sinus syndrome is defined as
syncope or presyncope resulting from an extreme reflex re-
sponse to carotid sinus stimulation. It is an uncommon cause of
syncope. There are two components of the reflex:
1. Cardioinhibitory, resulting from increased parasympa-
thetic tone and manifested by slowing of the sinus rate or
prolongation of the PR interval and advanced AV block, alone
or in combination.
2. Vasodepressor, secondary to a reduction in sympathetic
activity resulting in loss of vascular tone and hypotension. This
effect is independent of heart rate changes.
Before concluding that permanent pacing is clinically indi-
cated, the physician must determine the relative contribution
of the two components of carotid sinus stimulation to the
individual patient’s symptom complex. Hyperactive response
to carotid sinus stimulation is defined as asystole due to sinus
arrest or AV block of more than 3 seconds or a substantial
symptomatic decrease in systolic blood pressure, or both (106).
Pauses up to 3 seconds during carotid sinus massage are
considered to be within normal limits. Such heart rate and
hemodynamic responses may occur in normal subjects and
patients with coronary artery disease. The cause-and-effect
relation between the hypersensitive carotid sinus and the
patient’s symptoms must be made with great caution (107).
Spontaneous syncope reproduced by carotid sinus stimulation
should alert the physician to the presence of this syndrome.
Minimal pressure on the carotid sinus in elderly patients or
patients receiving digitalis may result in marked changes in
heart rate and blood pressure, yet not be of clinical signifi-
cance. Permanent pacing for patients with pure excessive
cardioinhibitory response to carotid stimulation is effective in
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relieving symptoms (108,109). Because 10% to 20% of patients
with this syndrome may have an important vasodepressor
component of their reflex response, it is desirable to define this
component before concluding that all symptoms are related to
asystole alone. In patients whose reflex response includes both
cardioinhibitory and vasodepressor components, attention to
the latter is essential for effective therapy in patients undergo-
ing pacing.
Neurally mediated syncope accounts for 10% to 40% of
syncope patients. Neurally mediated syncope and neurally
mediated syndromes refer to a variety of clinical scenarios in
which triggering of a neural reflex results in a usually self-limited
episode of systemic hypotension characterized by both bradycar-
dia and peripheral vasodilation (110). Vasovagal syncope is a
term used to denote one of the most common clinical scenarios
within the category of neurally mediated syncopal syndromes.
Considerable controversy exists concerning the role of
permanent pacing in refractory neurally mediated syncope
associated with significant bradycardia or asystole. Approxi-
mately 25% of patients have a predominant vasodepressor
reaction without significant bradycardia (111). An additional
large percentage of patients will have a mixed vasodepressor/
vasoinhibitory component of their symptoms. While one group
of investigators have noted some benefit of pacing in these
patients (112,113), another study using a pacing rate 20%
higher than the resting heart rate demonstrated that pacing did
not prevent syncope any better than pharmacotherapy (106).
Because most individuals with neurally mediated syncope have
a slowing of heart rate after the fall in blood pressure, pacing
may be ineffective in most patients. However, dual-chamber
pacing, carefully prescribed on the basis of tilt-table test
results, may be effective in reducing symptoms if the patient
has a significant cardioinhibitory component to the cause of
their symptoms (114). Preliminary results from a recent ran-
domized trial (115) in highly symptomatic patients with brady-
cardia demonstrated that permanent pacing increased the time
to first syncopal event (P , .0007). The actuarial rate of
recurrent syncope at 1 year was 18.5% for pacemaker patients
and 59.7% for control patients. Although spontaneous or
provoked prolonged pauses are a concern in this population,
the prognosis without pacing is excellent (116). However,
several investigators have concluded that some patients with
syncope of undetermined origin may benefit from pacing if
findings strongly suggestive of bradycardic etiology are discov-
ered or provoked at electrophysiological study (117,118).
The evaluation of patients with syncope of undetermined
origin should take into account clinical status and not overlook
other more serious causes of syncope such as ventricular
tachyarrhythmias.
Indications for Permanent Pacing in Hypersensitive
Carotid Sinus Syndrome and Neurally
Mediated Syncope
Class I
1. Recurrent syncope caused by carotid sinus stimulation;
minimal carotid sinus pressure induces ventricular
asystole of >3 seconds’ duration in the absence of any
medication that depresses the sinus node or AV con-
duction. (Level of evidence: C) (108,109)
Class IIa
1. Recurrent syncope without clear, provocative events
and with a hypersensitive cardioinhibitory response.
(Level of evidence: C) (108,109)
2. Syncope of unexplained origin when major abnormali-
ties of sinus node function or AV conduction are
discovered or provoked in electrophysiological studies.
(Level of evidence: C)
Class IIb
1. Neurally mediated syncope with significant bradycardia
reproduced by a head-up tilt with or without isoproterenol
or other provocative maneuvers. (Level of evidence: B)
(112–115)
Class III
1. A hyperactive cardioinhibitory response to carotid si-
nus stimulation in the absence of symptoms.
2. A hyperactive cardioinhibitory response to carotid si-
nus stimulation in the presence of vague symptoms
such as dizziness, light-headedness, or both.
3. Recurrent syncope, light-headedness, or dizziness in
the absence of a hyperactive cardioinhibitory response.
4. Situational vasovagal syncope in which avoidance be-
havior is effective.
G. Pacing in Children and Adolescents
The indications for permanent cardiac pacemaker implan-
tation in the child or adolescent may be broadly considered as
(1) symptomatic sinus bradycardia, (2) recurrent bradycardia-
tachycardia syndromes, (3) congenital AV block, and (4)
advanced second- or third-degree AV block, either surgical or
acquired. Although the general indications for pacemaker
implantation in children are similar to those in adults, there
are several important considerations in young patients. First,
an increasing number of patients are surviving complex surgi-
cal procedures for congenital heart disease that result in
palliation rather than correction of circulatory physiology.
The residua of impaired ventricular function and abnormal
physiology may result in symptomatic bradycardia at rates
that do not produce symptoms in persons with normal
cardiovascular physiology. Hence, the indications for pace-
maker implantation in these patients need to be based on
correlation of symptoms with relative bradycardia rather
than absolute heart rate criteria. Second, the clinical signif-
icance of bradycardia is age dependent: a heart rate of
45 bpm may be a normal finding in an adolescent, whereas
the same rate in a newborn or infant indicates profound
bradycardia.
Bradycardia and associated symptoms in children are often
transient (eg, paroxysmal AV block or sinus arrest) and
difficult to document. Although sinus node dysfunction (sick
sinus syndrome) is increasingly recognized in pediatric pa-
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tients, it is not itself an indication for pacemaker implantation.
In the young patient with sinus bradycardia, the primary
criterion for a pacemaker is the concurrent observation of a
symptom (eg, syncope) with bradycardia (eg, heart rate ,35 to
40 bpm or asystole .3 seconds) (25,27,119). In general,
correlation of symptoms with bradycardia is determined by
24-hour ambulatory or transtelephonic electrocardiography.
Symptomatic bradycardia (as defined) is considered an indica-
tion for pacemaker implantation, provided that other causes of
the symptom(s) have been excluded. Alternative causes to be
considered include seizures, breath holding, apnea, or neurally
mediated mechanisms.
Bradycardia-tachycardia syndrome (sinus bradycardia alter-
nating with atrial flutter or reentrant atrial tachycardia) is an
increasingly frequent problem in young patients following
surgery for congenital heart disease. Substantial morbidity and
mortality have been observed in young patients with recurrent
or chronic atrial flutter with the loss of sinus rhythm an
independent risk factor for subsequent development of atrial
flutter (120,121). Thus, both long-term atrial pacing at physi-
ological rates as well as atrial antitachycardia pacing have been
reported for treatment of sinus bradycardia and prevention or
termination of recurrent episodes of tachycardia (122,123). To
date the results of pacing for the bradycardia-tachycardia
syndrome in children have been equivocal and the source of
considerable controversy (124,125). It is clear that long-term
drug therapy (eg, propranolol or amiodarone) deemed essen-
tial for the control of atrial flutter may result in symptomatic
bradycardia in some patients, whereas in others the use of
antiarrhythmic agents (eg, quinidine) may potentially increase
the risk of ventricular arrhythmias or sudden death in the
presence of profound bradycardia. Thus, in young patients
with recurrent arrhythmias associated with the bradycardia-
tachycardia syndrome, permanent pacing should be considered
as an adjunctive form of therapy.
Indications for permanent pacing in young patients with
congenital complete AV block have evolved on the basis of
improved definition of the natural history of the disease as
well as advances in pacemaker technology and diagnostic
methods. For example, in recent studies it has been ob-
served that pacemaker implantation may improve long-term
survival and prevent syncopal episodes among asymptomatic
patients with congenital complete AV block (126,127).
Several criteria (average heart rate, pauses in the intrinsic
rate, associated structural heart disease, prolonged QT
interval, and exercise tolerance) must be considered in the
asymptomatic patient with congenital complete AV block
(128 –130).
The use of cardiac pacing with b-blockade for prevention of
symptoms in patients with the congenital long QT syndrome is
supported by recent studies (98,131). This applies in particular
to patients with pause-dependent initiation of ventricular
tachyarrhythmias (132) or those with sinus bradycardia or
advanced AV block in association with the congenital long QT
syndrome (133,134). Although pacemaker implantation may
reduce the incidence of symptoms in these patients, long-term
benefit on risk of sudden cardiac arrest remains to be deter-
mined (98,131,133).
A poor prognosis has been established for patients with
permanent postsurgical AV block who do not receive perma-
nent pacemakers for rate support (135). Hence, the presence
of advanced second- or third-degree AV block persisting for 7
to 14 days after cardiac surgery is considered a Class I
indication for pacemaker implantation (136). However, the
need for pacing in patients with transient AV block with
residual bifascicular block is less certain, whereas patients in
whom AV conduction returns to normal generally have a
favorable prognosis (137).
Additional considerations that need to be made in pace-
maker implantation in young patients include risk of paradoxic
embolism with an endocardial lead system in the presence of
residual intracardiac defects and the lifelong need for perma-
nent cardiac pacing (138,139). Therefore, decisions about
pacemaker implantation must also take into account implan-
tation technique (transvenous versus epicardial) and long-term
vascular access.
Indications for Permanent Pacing in Children
and Adolescents
Class I
1. Advanced second- or third-degree AV block associated
with symptomatic bradycardia, congestive heart fail-
ure, or low cardiac output. (Level of evidence: C)
2. Sinus node dysfunction with correlation of symptoms
during age-inappropriate bradycardia. The definition
of bradycardia varies with the patient’s age and ex-
pected heart rate. (Level of evidence: B) (25,27,119)
3. Postoperative advanced second- or third-degree AV
block that is not expected to resolve or persists at least
7 days after cardiac surgery. (Level of evidence: B, C)
(135,136)
4. Congenital third-degree AV block with a wide QRS
escape rhythm or ventricular dysfunction. (Level of
evidence: B) (127,129)
5. Congenital third-degree AV block in the infant with a
ventricular rate <50 to 55 bpm or with congenital heart
disease and a ventricular rate <70 bpm. (Level of
evidence: B, C) (129,130)
6. Sustained pause-dependent VT, with or without pro-
longed QT, in which the efficacy of pacing is thoroughly
documented. (Level of evidence: B) (97,98,131,132)
Class IIa
1. Bradycardia-tachycardia syndrome with the need for
long-term antiarrhythmic treatment other than digi-
talis. (Level of evidence: C) (123,124)
2. Congenital third-degree AV block beyond the first year
of life with an average heart rate <50 bpm or abrupt
pauses in ventricular rate that are two or three times
the basic cycle length. (Level of evidence: B) (128)
3. Long QT syndrome with 2:1 AV or third-degree AV
block. (Level of evidence: B) (133,134)
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4. Asymptomatic sinus bradycardia in the child with
complex congenital heart disease with resting heart
rate <35 bpm or pauses in ventricular rate >3 seconds.
(Level of evidence: C)
Class IIb
1. Transient postoperative third-degree AV block that
reverts to sinus rhythm with residual bifascicular
block. (Level of evidence: C) (137)
2. Congenital third-degree AV block in the asymptomatic
neonate, child, or adolescent with an acceptable rate,
narrow QRS complex, and normal ventricular func-
tion. (Level of evidence: B) (126,127)
3. Asymptomatic sinus bradycardia in the adolescent with
congenital heart disease with resting heart rate <35
bpm or pauses in ventricular rate >3 seconds. (Level of
evidence: C)
Class III
1. Transient postoperative AV block with return of nor-
mal AV conduction within 7 days. (Level of evidence: B)
(136,137)
2. Asymptomatic postoperative bifascicular block with or
without first-degree AV block. (Level of evidence: C)
3. Asymptomatic type I second-degree AV block. (Level of
evidence: C)
4. Asymptomatic sinus bradycardia in the adolescent
with longest RR interval <3 seconds and minimum
heart rate >40 bpm. (Level of evidence: C) (140)
H. Pacing in Specific Conditions
Hypertrophic Obstructive Cardiomyopathy Early observa-
tional studies suggested that pacing the right ventricular apex
would reduce the LV outflow gradient. In patients with
severely symptomatic hypertrophic cardiomyopathy, implanta-
tion of a dual-chamber pacemaker with a short AV delay has
been shown to decrease the magnitude of LV outflow obstruc-
tion and alleviate symptoms (141–143). These findings come
from nonrandomized unblinded studies. The mechanisms by
which pacing improves the LV outflow gradient are not
completely understood. Pacing therapy can change the ventric-
ular contraction pattern by prematurely activating part of the
ventricle, creating a regional dyssynchrony. This early paced
portion of the ventricle faces low chamber pressure and stress
and contracts against a lower afterload (144). Altered LV
activation causes disordered ventricular contractility with late
septal activation, increases LV systolic dimension, and reduces
systolic anterior motion of the mitral valve. Thus, LV outflow
obstruction is reduced and the atrial contribution to LV filling
is maintained. Selection of an optimal AV delay appears to be
critical in achieving an optimal hemodynamic result (142,145).
The optimal AV delay appears to be the longest AV interval
that consistently results in a completely paced QRS morphol-
ogy (146). Some patients with too short a native AV delay may
benefit from AV junction ablation so that the paced and
sensed AV delay can be optimized (147). Pacing may cause
thinning of the LV wall and decrease outflow obstruction
(142,148). Two recent observational studies have suggested
that a decrease in LV outflow gradient produced by tempo-
rary dual-chamber pacing may have adverse effects on
ventricular filling and cardiac output (149,150). Another
small observational study of dual-chamber pacing in hyper-
trophic cardiomyopathy patients without outflow obstruc-
tion failed to show significant hemodynamic or short-term
benefit (151).
One study (142) demonstrated that dual-chamber pacing
eliminated or ameliorated symptoms in 74 of 88 patients.
Patients in this study were not required to have a beneficial
hemodynamic response to temporary pacing as a selection
criterion for permanent pacing. A recent randomized study
(152) demonstrated that DDD pacing reduced outflow tract
gradient and improved New York Heart Association (NYHA)
functional class. One long-term study (153) in eight patients
supported the long-term benefit of dual-chamber pacing in this
group of patients. The outflow gradient was reduced even after
cessation of pacing, suggesting some ventricular remodeling
had occurred secondary to pacing. Although these data are
encouraging, a recent randomized, double-blind crossover study
(154) of 19 patients demonstrated no significant subjective
or exercise capacity improvement in the paced versus non-
paced group at 2 to 3 months of follow-up, despite a
significant decrease in LV outflow gradient. However, sev-
eral individual patients in this study demonstrated symptom-
atic and hemodynamic improvement from dual-chamber
pacing. Dual-chamber pacing may improve symptoms and
LV outflow gradient in pediatric patients. However, rapid
atrial rates, rapid AV conduction, and congenital mitral
valve abnormalities may preclude effective pacing in some
patients (155).
The lack of large, prospective, placebo-controlled data
makes this indication for permanent pacing controversial.
Currently there are no data available to support that pacing
alters the clinical course of the disease or improves survival.
Therefore, routine implantation of dual-chamber pacemak-
ers should not be advocated in all patients with symptomatic
hypertrophic obstructive cardiomyopathy.
Pacing Indications for Hypertrophic Cardiomyopathy
Class I
Class I indications for sinus node dysfunction or AV block




1. Medically refractory, symptomatic hypertrophic cardio-
myopathy with significant resting or provoked LV out-
flow obstruction. (Level of evidence: C) (142,145,146)
Class III
1. Patients who are asymptomatic or medically controlled.
2. Symptomatic patients without evidence of LV outflow
obstruction.
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Idiopathic Dilated Cardiomyopathy Several observational
studies have shown limited improvement in patients with
symptomatic dilated cardiomyopathy refractory to medical
therapy with dual-chamber pacing with a short AV delay
(156–159). Theoretically, a short AV delay may optimize the
timing of mechanical AV synchrony and ventricular filling
time. In patients with prolonged PR intervals .200 millisec-
onds, diastolic filling time may be improved by dual-chamber
pacing with a short AV delay (17). In one study (157), cardiac
output was increased 38% by shortening AV delay when the
average PR interval was 283 milliseconds before pacing. Per-
manent pacing in symptomatic patients with drug-refractory
dilated cardiomyopathy and a prolonged PR interval may be
useful if short-term benefit is demonstrated in acute studies.
However, at this time no long-term data are available, and
there is no consensus of opinion for this indication. The
mechanisms by which dual-chamber pacing might benefit
patients with dilated cardiomyopathy are poorly understood.
One hypothesis is that a well-timed atrial contraction primes
the ventricles and decreases mitral regurgitation, thus aug-
menting stroke volume and arterial pressure. Several studies
have not demonstrated improvement in cardiac output with
dual-chamber pacing in patients with congestive heart failure
(160,161). One randomized controlled trial of 12 patients
showed no significant benefit of VDD pacing through a range
of PR intervals despite the presence of both tricuspid and
mitral regurgitation (160). One study (162) in 89 patients with
LV dysfunction suggested that VVI pacing in the right ventric-
ular outflow tract (simulating a normal high to low ventricular
activation) improved cardiac output by 18.8% when compared
with pacing the right ventricular apex. Preliminary data (163,164)
suggest that simultaneous biventricular pacing may improve car-
diac hemodynamics and thus lead to subjective and objective
symptom improvement. Prospective controlled trials are under way
to confirm these initial findings and further define the benefit of
biventricular pacing in patients with symptomatic, drug-refractory
dilated cardiomyopathy. Overall there are sparse long-term data
to show improvement in hemodynamics, symptom relief, or
survival for pacing in dilated cardiomyopathy. Even less data exist
in patients with ischemic cardiomyopathy.
Pacing Indications for Dilated Cardiomyopathy
Class I
Class I indications for sinus node dysfunction or AV block




1. Symptomatic, drug-refractory dilated cardiomyopathy
with prolonged PR interval when acute hemodynamic
studies have demonstrated hemodynamic benefit of
pacing. (Level of evidence: C) (17,156–158)
Class III
1. Asymptomatic dilated cardiomyopathy.
2. Symptomatic dilated cardiomyopathy when patients are
rendered asymptomatic by drug therapy.
3. Symptomatic ischemic cardiomyopathy.
Cardiac Transplantation The incidence of bradyarrhyth-
mias after cardiac transplantation varies from 8% to 23%
(165–167). The majority of bradyarrhythmias are associated
with sinus node dysfunction. Because of symptoms and im-
paired recovery and rehabilitation, some transplant programs
recommend more liberal use of cardiac pacing for persistent
postoperative bradycardia. About 50% of patients show im-
provement within 6 to 12 months, and long-term pacing is
often unnecessary in a large number of patients (168–170).
Significant bradyarrhythmias and asystole have been associated
with reported cases of sudden death (171). No predictive
factors have been identified to indicate which patients will
develop post-transplantation bradyarrhythmias. In some pa-
tients the need for pacing may be transient. The benefits of the
atrial contribution to cardiac output and chronotropic compe-
tence may optimize the patient’s functional status. Attempts to
temporarily treat bradycardia with measures such as theoph-
ylline (172) may minimize the need for pacing. Post-transplant
patients who have irreversible sinus node dysfunction or AV
block with previously stated Class I indications should have
permanent pacemakers.
Pacing Indications After Cardiac Transplantation
Class I
1. Symptomatic bradyarrhythmias/chronotropic incompe-
tence not expected to resolve and other Class I indica-




1. Symptomatic bradyarrhythmias/chronotropic incompe-
tence that, although transient, may persist for months
and require intervention. (Level of evidence: C)
Class III
1. Asymptomatic bradyarrhythmias after cardiac trans-
plantation.
I. Selection of Pacemaker Device
Once the decision has been made to implant a pacemaker
in a given patient, the clinician must decide among a large
number of available pacemaker generators and leads. Gener-
ator choices include single- versus dual-chamber devices,
unipolar versus bipolar configuration, presence and type of
sensor for rate response, advanced features such as automatic
mode switching, size, battery capacity, and cost. Lead choices
include polarity, type of insulation material, fixation mecha-
nism (active versus passive), presence of steroid elution, and
typical pacing impedance. Other factors that importantly in-
fluence the choice of pacemaker system components include
the capabilities of the pacemaker programmer, which provides
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the link between the pacemaker system and the physician, and
local availability of technical support.
Even after selecting and implanting the pacing system, the
physician has a number of options for programming the device.
In modern single-chamber pacemakers, programmable fea-
tures include pacing mode, lower rate, pulse width and ampli-
tude, sensitivity, and refractory period. Dual-chamber pace-
makers have the same programmable features as well as
maximum tracking rate, AV delay, and others. Rate-responsive
pacemakers require programmable features to regulate the
relation between sensor output and pacing rate and to limit the
maximum sensor-driven pacing rate. These programmable
parameters must be individually adjusted for each patient, and
the choice of one programmable parameter will often depend
on the availability of another parameter. For example, in a
patient with complete AV block and paroxysmal atrial fibril-
lation, a dual-chamber pacemaker without mode-switching
capability most appropriately might be programmed to DDIR*
mode, whereas in the same patient, a pacemaker with mode-
switching capability most appropriately might be programmed
to DDDR mode with mode switching. In recent years, with the
advent of more sophisticated pacemaker generators, optimal
programming of pacemakers has become increasingly complex
and device specific and requires specialized knowledge on the
part of the physician.
Many of these considerations are beyond the scope of this
document. The discussion below focuses on the most funda-
mental choices the clinician has with respect to the pacemaker
prescription: those that have the greatest impact on procedural
time and complexity, follow-up, patient outcome, and cost: (1)
the choice among single-chamber ventricular pacing, single-
chamber atrial pacing, and dual-chamber pacing, and (2)
whether or not to use a generator that incorporates a sensor
for rate-responsive pacing.
Table 1 gives brief guidelines on the appropriateness of
different pacemakers for the most commonly encountered
indications for pacing. Figure 1 is a decision tree for selecting
a pacing system in a patient with AV block. Figure 2 is a
decision tree for selecting a pacing system in a patient with
sinus node dysfunction.
An important challenge in selecting a pacemaker system is
anticipating progression of abnormalities of automaticity and
conduction and selecting a system that will best accommodate
these developments. Thus, it is reasonable to select a pace-
maker with more extensive capabilities than needed at the time
of implantation but that may prove useful in the future. Some
patients with sinus node dysfunction and paroxysmal atrial
fibrillation, for example, may develop AV block in the future
(as a result of natural progression of disease, drug therapy, or
catheter ablation) and may ultimately benefit from a dual-
chamber pacemaker with mode-switching capability. Patients
who are likely to develop ventricular tachyarrhythmias, for
which an ICD would be warranted, should receive a pacemaker
that is compatible with ICDs.
Newer Technical Innovations Rate-responsive pacemakers.
An increasing percentage of pacemakers implanted in the
United States incorporate sensors to detect states of exercise
and trigger accelerations in pacing rate. An industrywide
survey in 1996 indicates that 83% of all generators implanted
in 1996 in the United States had rate response as a program-
mable option. Among pacemaker patients who are chrono-
tropically incompetent (ie, unable to increase sinus node rate
appropriately with exercise), rate-responsive pacemakers allow
*This and other three- or four-letter notations conform to the NASPE/
BPEG generic pacemaker code (173).
Table 1. Guidelines for Choice of Pacemaker Generator in Selected Indications for Pacing
Sinus Node Dysfunction AV Block
Neurally Mediated Syncope or
Carotid Sinus Hypersensitivity
Single-chamber atrial pacemaker ● No suspected abnormality of AV conduction
and not at increased risk for future AV
block
● Maintenance of AV synchrony during pacing
desired
● Rate response available if desired




● Maintenance of AV synchrony during pacing
not necessary
● Rate response available if desired
● Chronic atrial fibrillation or other
atrial tachyarrhythmia or
maintenance of AV synchrony
during pacing not necessary
● Rate response available if desired
● Chronic atrial fibrillation or
other atrial tachyarrhythmia
● Rate response available if
desired
Dual-chamber pacemaker ● AV synchrony during pacing desired
● Suspected abnormality of AV conduction or
increased risk for future AV block
● Rate response available if desired
● AV synchrony during pacing
desired
● Atrial pacing desired
● Rate response available if desired
● Sinus mechanism present




Not appropriate ● Normal sinus node function and
no need for atrial pacing
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for increases in pacing rates with exercise and have been shown
to improve exercise capacity and quality of life.
In the United States, the vast majority of sensors incorpo-
rated into rate-responsive implantable pacemakers are piezo-
electric crystals or accelerometers that detect motion, vibra-
tion, pressure, or acceleration. Other technologies using
sensors that measure minute ventilation or QT interval may
provide a heart rate response more proportional to exercise
than piezoelectric sensors or accelerometers. An advantage of
all of these sensor technologies is that they do not require
specialized pacemaker leads, although minute ventilation sens-
ing requires a bipolar lead. An older technique that measured
circulating blood temperature has largely been abandoned.
The challenge of appropriately adjusting the response to
exercise of these generators in individual patients is becoming
increasingly recognized. To facilitate optimal programming of
rate-response capability, recently introduced generators incor-
porate procedures for initial programming of rate-response
parameters, subsequent automatic adjustment of these param-
eters, and retrievable diagnostic data (such as heart rate
histograms or heart rate plots) to assess the appropriateness of
the rate response.
Single-lead VDD pacemaker systems. Despite advances in
rate-responsive pacemakers, it is widely appreciated that the
best signal to guide heart rate response to exercise (and other
forms of physiological stress) is a normally functioning sinus
node. Most commonly, dual-chamber pacemakers incorporat-
ing separate atrial and ventricular leads are used to detect
atrial depolarization. However, single transvenous lead pacing
systems have been developed that are capable of sensing atrial
depolarization. The distal end of the lead is positioned in the
right ventricle for ventricular pacing and sensing; a pair of
electrodes is incorporated in the more proximal portion of the
lead body lying within the right atrial cavity for atrial sensing.
With current technology, single-lead VDD pacing systems are
not capable of atrial pacing. The atrial signal sensed by
single-lead VDD pacemakers has a less consistent amplitude
than that typically sensed by conventional dual-chamber pace-
makers and varies significantly with posture, but sensing per-
formance is generally satisfactory (174). Single-lead VDD
pacemaker systems are a reasonable alternative to dual-
chamber pacemakers in patients with AV block in whom atrial
pacing is not required and in whom simplicity of implantation
or avoidance of two leads is desired.
Automatic mode switching. When nonphysiological atrial
tachyarrhythmias, such as atrial fibrillation or flutter, occur
paroxysmally in a patient with a dual-chamber pacemaker
programmed to conventional DDD or DDDR mode, the
tachyarrhythmia will generally be tracked near the pro-
grammed maximum tracking rate, leading to an undesirable
acceleration of ventricular pacing rate. Newer dual-chamber
generators incorporate algorithms for detecting rapid, non-
physiological atrial rates and automatically switch modes to
one that does not track atrial activity, such as DDI or DDIR.
When the atrial tachyarrhythmia terminates, the pacemaker
automatically reverts back to the DDD or DDDR mode. This
Figure 1. Selection of pacemaker systems for patients with atrioven-
tricular (AV) block.
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automatic mode-switch feature is especially helpful in patients
with AV block and paroxysmal atrial fibrillation and expands
the usefulness of dual-chamber pacemakers in such patients.
Pacemaker leads. The vast majority of implanted pacemak-
ers use transvenous endocardial leads, with the remainder
using epicardial leads. Transvenous leads may be bipolar or
unipolar in configuration. Bipolar configurations have the
advantage of avoiding myopotential inhibition and skeletal
muscle stimulation, and an increasingly important advantage is
that, unlike most unipolar pacing systems, they are compatible
with concomitantly implanted ICDs. However, some manufac-
turers’ bipolar leads have higher failure rates than their
unipolar leads.
The insulation material used in pacemaker leads is either
silicone rubber or polyurethane. Polyurethane-insulated leads
have a thinner diameter and better handling characteristics
than silicone-insulated leads. However, some bipolar lead
models with polyurethane insulation have shown unacceptably
high failure rates due to degradation of the insulation. It is
possible that more recently introduced polyurethane leads,
using different polymers and different manufacturing pro-
cesses, will avoid these unacceptably high failure rates.
Active fixation leads, in which the distal tip of the lead
incorporates a small helical screw for fixation to the endocar-
dium, are an alternative to passive fixation leads. Active
fixation leads allow for more alternatives in the site of endo-
cardial attachment. For instance, whereas a passive fixation
ventricular lead generally must be positioned in the right
ventricular apex, an active fixation lead may be positioned in
the apex, outflow tract, or inflow tract of the right ventricle.
Active fixation leads have an additional advantage of greater
ease of extraction after long-term implantation. A disadvan-
tage of active fixation leads is that they generally have higher
chronic capture thresholds than do passive fixation leads.
An important advance in pacemaker leads is the develop-
ment of leads with lower capture thresholds, which result in
less battery consumption during pacing. Steroid eluting leads
incorporate at their distal tip a small reservoir of corticosteroid
that slowly elutes into the interface between the lead electrode
and the endocardium, reducing the inflammation and fibrosis
that normally occur at this interface. As a result, steroid-
eluting leads have significantly lower long-term capture thresh-
olds than leads not incorporating steroid. The benefit of
steroid elution was originally demonstrated in passive fixation
transvenous leads (175); more recently, the benefit has also
been demonstrated in active fixation transvenous leads (176)
and epicardial leads (177). Similar improvements in capture
thresholds have been achieved with modification in electrode
shape, size, and composition (178).
Methodology of Comparing Different Pacemaker Genera-
tors and Configurations Two or more pacemaker modes can
be compared with respect to exercise capacity, quality of life,
clinical end points (such as death, heart failure, atrial fibrilla-
tion, and stroke), and cost. For end points such as exercise
capacity or quality of life, pacemaker modes can be compared
using a randomized crossover study design, provided that the
patients have pacing systems that can be programmed to each
of these modes. (For example, dual-chamber, rate-responsive
pacemakers can be crossed over between VVIR and DDDR
pacing). Studies that compare clinical end points require
long-term follow-up without crossover. In long-term studies
Figure 2. Selection of pacemaker systems for patients with sinus node
dysfunction. AV indicates atrioventricular.
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patients can be randomly assigned to receive different types of
pacemakers (eg, single-chamber ventricular pacemakers versus
single-chamber atrial pacemakers), or all patients may receive
a single type of pacemaker system (eg, dual-chamber, rate-
responsive) and be randomly assigned to different modes (eg,
VVIR versus DDDR).
Quality-of-life measures have recently been emphasized as
important end points when comparing different modes of
pacing, and there are important considerations in the choice of
the instrument used to measure quality of life (179–181).
Although the quality of life experienced with different modes
of pacing may be compared using short-term crossover studies,
long-term studies that include quality-of-life end points may
reflect effects of chronic adaptation to stimulation not detect-
able in short-term comparisons. Several recent or ongoing
long-term randomized comparisons of pacing modes have
quality-of-life end points (83).
Pacing in Sinus Node Dysfunction Short-term outcomes.
Short-term crossover studies in patients with sinus node dys-
function have shown improved quality of life in dual-chamber
versus ventricular pacing (180,182). There are conflicting data
regarding any improvement in maximum exercise performance
in rate-responsive dual-chamber compared with rate-responsive
ventricular pacing (182,183).
Long-term outcomes. Over the past decade a number of
nonrandomized observational studies have been published com-
paring atrial-based pacing (either atrial pacemakers or dual-
chamber pacemakers) to ventricular pacing in patients with
sinus node dysfunction. These studies have recently been
reviewed (83,184,185). A consistent finding is that the inci-
dence of atrial fibrillation is lower in patients receiving atrial-
based pacemakers than in those receiving ventricular pace-
makers; atrial-based pacing is associated with a reduction in
risk of atrial fibrillation averaging 74% (185). The findings of
the studies were mixed with regard to mortality end points:
some studies showed a lower mortality in atrial-based pace-
maker patients and some showed no significant difference.
These studies suffer from limitations common to all nonran-
domized studies, most importantly, uncertainty as to the
clinical equivalence of the patient groups. In some of these
studies the patient groups appear to be well matched, whereas
in others there is insufficient information to assess their
comparability.
Andersen et al (84) published a randomized study compar-
ing pacemaker modes with long-term follow-up in patients with
sinus node dysfunction. Two hundred twenty-five patients were
randomly assigned to atrial and ventricular pacing. During a
mean of 40 months of follow-up, there were significantly fewer
thromboembolic events in the atrial paced patients. There was
a trend toward less atrial fibrillation in the atrial paced group,
but it did not reach statistical significance. The study was not
powered to detect a mortality difference between the two
patient groups. However, when follow-up was extended to 8
years, atrial pacing was associated with significantly decreased
“all-cause” and “cardiovascular” mortality compared to ven-
tricular pacing (84a).
In summary, available data suggest that in patients with
sinus node dysfunction, the incidence of atrial fibrillation in
patients receiving atrial or dual-chamber pacemakers may be
lower than in patients receiving ventricular pacemakers. Pub-
lished studies do not adequately address the issues of other
clinical end points, such as heart failure, mortality, or quality of
life.
Role of single-chamber atrial pacemakers. Single-chamber
atrial pacemakers, with rate-responsive capability if appropri-
ate, have been advocated for patients with sinus node dysfunc-
tion but no evidence of AV block (21,179,186–188). Use of
single-chamber pacemakers is limited by concerns about sub-
sequent development of AV block. The risk of developing
significant AV block after atrial pacemaker implantation for
sinus node dysfunction has been estimated to be 0.6% to 3.0%
per year, with bundle branch block but not AV Wenckebach
rate being predictive of a higher likelihood of subsequent AV
block (186,187,189,190). In selected patients with sinus node
dysfunction, use of single-chamber atrial pacemakers is an
acceptable approach that maintains normal AV synchrony
without the added cost and extra lead of a dual-chamber
pacemaker system but with a small risk of subsequent devel-
opment of AV block requiring pacemaker revision. With
rate-responsive atrial pacemakers, the risk of developing he-
modynamically significant first-degree AV block during rate
accelerations has not been extensively studied but may be
significant (191).
A randomized study of DDDR versus VVIR pacing in
patients with sinus node dysfunction is ongoing, with end
points of total mortality, atrial fibrillation, stroke, heart failure,
quality of life, and cost (83).
Pacing in Atrioventricular Block Short-term outcomes. A
number of short-term crossover studies have compared pacing
modes in patients with AV block with respect to quality of life
and exercise capacity. These studies have recently been re-
viewed in depth (83,180). Studies comparing dual-chamber
pacing with non–rate-responsive ventricular pacing have
shown improved exercise capacity and symptomatology with
dual-chamber pacing. Studies comparing rate-responsive ven-
tricular pacing with non–rate-responsive ventricular pacing
have shown similar advantages with rate-responsive ventricular
pacing. However, studies comparing dual-chamber pacing with
rate-responsive ventricular pacing have shown no significant
difference in exercise capacity; with respect to symptoms, most
but not all have shown an advantage of dual-chamber pacing.
It is likely that the symptomatic advantage of dual-chamber
pacing over rate-responsive ventricular pacing is derived from
the maintenance of AV association during rest and low-level
activity.
Long-term outcomes. Two nonrandomized observational
studies comparing patients with AV block who received dual-
chamber pacemakers or ventricular pacemakers have shown
improved survival associated with implantation of dual-
chamber pacemakers among those patients with heart failure
but no difference in survival between the two pacing modes
among patients without heart failure (74,192). In an ongoing
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study, patients with AV block are randomly assigned to receive
a ventricular pacemaker or a dual-chamber pacemaker; the
primary end point is total mortality (83).
Pacing in the Elderly More than 85% of pacemaker recip-
ients are at least 64 years old (193). Elderly pacemaker patients
are the rule, not the exception.
It has been suggested that elderly patients requiring pacing
should be considered for less sophisticated devices, eg, single-
chamber ventricular pacemakers or non–rate-responsive pace-
makers. However, studies in elderly patients show improved
exercise capacity and alleviated symptoms with rate-responsive
ventricular pacing or dual-chamber pacing compared with
non–rate-responsive ventricular pacing (75,194). A retrospec-
tive analysis of 36,312 elderly Medicare patients receiving
pacemakers suggested that dual-chamber pacing is associated
with improved survival compared with ventricular pacing, even
after correction for confounding variables (195).
A prospective, randomized long-term comparison of rate-
responsive ventricular pacing and rate-responsive dual-
chamber pacing in elderly patients has recently been com-
pleted (G.A. Lamas, PACE Study, unpublished data, 1997).
The primary end point of the trial was quality-of-life measures;
only transient improvement in a minority of the quality-of-life
measures was found to be associated with rate-responsive
dual-chamber pacing compared with rate-responsive ventricu-
lar pacing.
On the basis of these studies, rate-responsive ventricular
pacing and dual-chamber pacing appear to offer benefits over
fixed-rate ventricular pacing with respect to quality of life in
elderly patients, but there may not be any benefit of dual-
chamber pacing over rate-responsive ventricular demand pac-
ing. It does not appear appropriate to uniformly withhold use
of dual-chamber or rate-responsive pacemakers in the elderly,
although such a decision is appropriate in any patient who is
extremely sedentary or has a limited life expectancy.
Optimizing Pacemaker Technology and Cost The cost of a
pacemaker system increases with its degree of complexity and
sophistication. For example, the cost of a dual-chamber pace-
maker system exceeds that of a single-chamber system with
respect to the cost of the generator (additional $1000), the
second lead (approximately $900), additional implantation
time and supplies, and additional follow-up. Similarly, the cost
of a rate-responsive generator exceeds that of a non–rate-
responsive generator by $500 to $1000. Against these addi-
tional costs are the potential benefits of the more sophisticated
systems with respect to quality of life, morbidity, and mortality.
Little is known about the cost-effectiveness of the additional
features of more complex pacemaker systems. Several ongoing
trials assessing the clinical benefits of dual-chamber or rate-
responsive pacing include economic analyses to estimate the
incremental cost-effectiveness of these features (83).
Approximately 16% of pacemaker implantations are for
replacement of generators; of those, 76% are replaced because
their batteries have reached end of service (193). Hardware
and software (ie, programming) features of pacemaker systems
that prolong useful battery longevity may improve the cost-
effectiveness of pacing. For example, optimal programming of
output voltages, pulse widths, and AV delays can markedly
decrease battery drain; a recent study showed that expert
programming of pacemaker generators can have a major
impact on longevity, prolonging it by an average of 4.2 years
compared with nominal settings (196). Extensive diagnostic
capabilities, which typically add $500 to $1000 to the cost of a
pacemaker generator, may allow for optimal programming by
the experienced physician with regard to improved device
longevity. Newer lead designs, such as those incorporating
steroid elution or high pacing impedance, allow for less current
drain; the cost of such leads is approximately $125 greater than
that of conventional leads. Future generators that automati-
cally determine whether a pacing impulse results in capture
may allow for programming outputs closer to threshold values
than conventional generators, and this new technology may
also have a major impact on device longevity. Although all of
these features arguably should prolong generator life, there are
other constraints on the useful life of a pacemaker generator,
including battery drain not directly related to pulse generation
and the limited life expectancy of many pacemaker recipients;
rigorous studies supporting the overall cost-effectiveness of
advanced pacing features are lacking.
The cost of pacemaker implantation may vary between
different locations within a hospital (eg, cardiac catheterization
laboratory versus operating room); costs can be minimized by
selecting the most economical site for implantation that pre-
serves excellent patient outcome. There has been a trend to
shorter hospital stays for pacemaker implantations, and some
implantations are now being performed on an outpatient basis.
Reuse of explanted pacemakers, not currently performed to
any extent in the United States, may eventually add signifi-
cantly to the cost-effectiveness of cardiac pacing (197).
J. Pacemaker Follow-up
After implantation of a pacemaker, careful follow-up and
continuity of care are required. The committee considered the
advisability of extending the scope of these guidelines to
include recommendations for follow-up and device replace-
ment. In general, follow-up is dictated by the patient’s disease
substrate, the device used, and evolving technology. The North
American Society of Pacing and Electrophysiology has pub-
lished a comprehensive series of reports on antibradycardia
pacemaker follow-up (198–200). In addition, the Health Care
Financing Administration has established guidelines for mon-
itoring of patients covered by Medicare who have antibrady-
cardia pacemakers (201). These documents are endorsed by
this writing group.
Many of the same considerations are relevant to both
pacemaker and ICD follow-up. Programming undertaken at
implantation should be reviewed before discharge and changed
accordingly at subsequent follow-up visits as indicated by
interrogation and testing. With careful attention to program-
ming pacing amplitude, pulse width, and diagnostic functions,
battery life can be significantly enhanced without compromis-
1192 GREGORATOS ET AL. JACC Vol. 31, No. 5
PACEMAKER IMPLANTATION GUIDELINES April 1998:1175–209
ing patient safety. The frequency of follow-up is dictated by
multiple factors, including other cardiovascular or medical
problems managed by the physician involved, the age of the
pacemaker, and the results of transtelephonic testing. In
patients who are pacemaker dependent, clinical evaluation
may be more frequent than for those who are not pacemaker
dependent. In general, follow-up usually includes assessment
of battery status, pacing threshold and pulse width, sensing
function, and lead integrity.
Because the indications for device implantation are evolv-
ing and some of the original indications for a particular patient
may have been controversial, future replacement decisions
may be more or less certain and must be individualized.
II. Indications for Implantable
Cardioverter-Defibrillator Therapy
A. Background
ICDs were originally developed and have been most fre-
quently used for prevention of sudden cardiac death in patients
with life-threatening ventricular arrhythmias such as sustained
VT or VF (202–205). Epidemiological studies report high rates
of recurrence of these life-threatening arrhythmias (30% to
50% in 2 years) during follow-up. Early observational reports
documenting efficacy in reversion of sustained VT and VF
(103–105,202,203,205–215) have now been supplemented by
large prospective and sometimes randomized single-center and
multicenter studies with long-term outcome data (204,216–
221). Enrollment in these trials has included patients with
coronary and noncoronary heart diseases with a wide range of
ventricular function and coexisting disorders.
These studies uniformly document sudden cardiac death
recurrence rates that average 1% to 2% annually after device
implantation in these populations. Simultaneously, rapid tech-
nological evolution of ICD systems has occurred. The ICD has
evolved from a short-lived nonprogrammable device requiring
a thoracotomy for lead insertion into a multiprogrammable
antiarrhythmia device inserted almost exclusively without tho-
racotomy, now capable of treating bradycardia, VT, and VF
(222–224). Clinical studies have recorded major improvements
in implant risk, system longevity, symptoms associated with
arrhythmia recurrences, quality of life, and diagnosis and
management of inappropriate device therapy (103,216 –
218,225–229). Implantation, follow-up, and replacement of
these devices is a complex process requiring familiarity with
device capabilities, adequate case volume, continuing educa-
tion, and skill in the management of ventricular arrhythmias,
therefore mandating involvement of a trained electrophysiolo-
gist (230) to provide an optimal personnel team for patient
safety and device management. A substantial new body of
information has emerged regarding the clinical outcome of
patients with VT or VF treated with currently available
antiarrhythmic therapies. There are currently three major
therapeutic options to reduce or prevent VT or VF in patients
at risk for these arrhythmias. These are
1. Antiarrhythmic drug therapy selected by electrophysiologi-
cal study or ambulatory monitoring or prescribed empiri-
cally.
2. Ablative techniques applied at cardiac surgery or percuta-
neously using catheter techniques.
3. Implantation of a cardioverter-defibrillator device system.
A combination of ICD therapy with drugs or ablation is also
frequently used. Currently the largest clinical experience is
with combined antiarrhythmic drug and ICD therapy.
B. Clinical Efficacy of ICD Therapy
ICD devices have been extensively evaluated in prospective
clinical trials, and clinical experience now exceeds 100,000
implants worldwide since the inception of this therapy (103–
105,202–221). ICDs have been clearly documented to revert
sustained ventricular tachyarrhythmias, including pace termi-
nation of sustained VT and shock reversion of VF. Large series
have shown nonthoracotomy systems can be implanted with an
average procedural mortality of 0.5% (217) to 0.8% (216). The
ICD has been shown to terminate VF successfully in 98.8%
(217) and 98.6% (216) of episodes. VT has been converted
with antitachycardia pacing in 89.4% (216) to 91.2% (217) of
episodes, with further successful conversions (98%) using
shock therapy. Inappropriate therapy, typically for atrial fibril-
lation, with a rapid ventricular response, has been noted in 5%
to 11% of patients.
Early retrospective reports showed significant improvements
in survival with the defibrillator (205,208,231). The study
design tended to overestimate benefits by using device thera-
pies (antitachycardia pacing and shocks) as surrogate mortality
events. In a large body of subsequent experience, the sudden
death rate reported in virtually all series ranges from 1% to 2%
per year with a cumulative incidence of #10% at 5 years
(105,205–207,210,211,213,215–217,232). Higher sudden death
rates have been reported in patients with severe LV dysfunc-
tion (233,234). Dilution of the survival benefit conferred by
sudden death reduction in ICD patients by non-arrhythmic
mortality and its impact on overall survival is patient
population–dependent (232,233).
Device therapy delivery cannot be used as a surrogate
mortality end point because arrhythmias other than VT/VF
can activate the device, and recurrent VT is not invariably
fatal. Symptomatic ICD activations alone underestimate anti-
arrhythmic benefits of ICD therapy. More recently, firmer
estimates of benefits from ICD therapy using devices with
event memory capabilities have become possible in the ab-
sence of placebo-controlled studies (225,227,235,236). In these
studies ICD patients had successful reversion (.98%) of VT
with circulatory collapse or VF, with a significant projected
survival benefit compared with untreated populations (235).
This benefit is incremental and continues to increase over
longer periods (3 to 4 years). A similar benefit exists in patients
with sustained VT (236).
There has been controversy about the appropriate end
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point for evaluation of ICD efficacy. Many studies have used
sudden death, but classification of the cause of death is often
difficult and imprecise. Consequently, a consensus has
emerged that total mortality is the appropriate primary end
point for judging ICD efficacy (237). Rates of sudden death
and ICD discharges provide useful information, but they
should be considered as secondary end points. Total mortality
varies significantly between reports due to differences in the
disease status of the population under study and LV function.
The presence of concomitant cardiac disease is a major
determinant of survival (233,238,239). Survival of ICD recipi-
ents is influenced by LV function. Patients with LV ejection
fractions #30% have reduced survival compared with those
with higher ejection fractions at 3 years (233,234). However,
both populations appear to derive a significant survival benefit
(221).
C. Alternatives to ICD Therapy
Pharmacological options for guided antiarrhythmic therapy
include drugs in Classes I, II, and III. Therapy can be guided by
Holter monitoring or serial electrophysiological testing. High
arrhythmia recurrence rates and moderate sudden death rates
are observed with Class I agents (240). By contrast, Class III
agents are associated with significantly lower arrhythmia recur-
rences, sudden death, and total mortality (240–243).
b-Blocking agents have also demonstrated efficacy in reduc-
ing mortality after AMI (244,245). However, their value in a
population of patients with sustained ventricular tachyarrhyth-
mias is not well established. Suppression of inducible VT as
well as control of spontaneous VT is often not achieved (246).
Although the overall survival of cardiac arrest patients treated
empirically with b-blockers and Class I agents may be compa-
rable, patients given Class I agents on serial electrophysiolog-
ical testing have a better outcome than those treated with
empiric b-blocker therapy (247). Current data do not support
a significant role for monotherapy with b-blockers in this
condition.
In the post–myocardial infarction patient, empiric amioda-
rone can reduce arrhythmic mortality, but benefit with respect
to total mortality in such patients with ventricular dysfunction
is less clear (248–251). In cardiac arrest survivors treated
empirically with amiodarone, patients with a reduced ejection
fraction (,40%) continue to exhibit high arrhythmia recur-
rence and sudden death rates (252). Similarly, patients with
congestive heart failure may show little to no mortality reduc-
tion with empiric amiodarone therapy (253,254).
Long-term maintenance of effective antiarrhythmic drug
therapy remains problematic. Discontinuation for drug intol-
erance is high for Class I agents and sotalol at initiation of
therapy and during long-term administration (240). Amioda-
rone therapy is also frequently discontinued for adverse effects
on long-term administration (243).
Ablative therapy has been most often used for patients with
sustained monomorphic VT induced at cardiac surgery or
electrophysiological study and mapped to a specific ventricular
site(s). Intraoperative ablation is accomplished mechanically
or with physical energy sources (cryothermia or laser), whereas
catheter-based energy delivery (direct-current shock, radiofre-
quency, microwaves, laser) is used during electrophysiological
procedures (255–258). These methods are applicable to a
select population of patients with malignant ventricular tachy-
arrhythmias that have reproducibly inducible monomorphic
VT suitable for cardiac mapping. Surgical experience is more
extensive and favorable in patients with coronary heart disease
than noncoronary disease. Perioperative mortality is now lower
and averages ,5% in more recent experience, particularly
when preoperative LV systolic function is preserved. Intraop-
erative map-guided ablation is associated with low arrhythmia
recurrence (,10% at 2 years) and minimal sudden death rates
(256–258) during long-term follow-up, making it an important
therapeutic alternative in this subgroup.
Catheter ablation approaches are still in technological
evolution (259,260). Hemodynamically stable VT is required
for mapping, and radiofrequency energy is currently used for
ablation (261,262). Procedural complication rates are moder-
ate with modest arrhythmia control (261,262), often in con-
junction with previously ineffective drug therapy in patients
with coronary artery disease. Higher efficacy rates are observed
in patients with right ventricular outflow tract tachycardia,
idiopathic left septal VT, and bundle branch reentrant VT in
whom ablation may be the preferred therapy (263–265). Mul-
tiple VT morphologies, polymorphic VT, and progressive
cardiomyopathy, when present, are less amenable to a favor-
able result with ablative intervention (255,256).
D. Comparison of Drug and Device Therapy for
Secondary Prevention of Cardiac Arrest and
Sustained Ventricular Tachycardia
A significant body of information now exists comparing
these two therapeutic options. Direct comparison of drug and
device therapy has been performed in several retrospective
nonrandomized reports and fewer prospective randomized stud-
ies. In comparison with concurrently medically treated but
nonrandomized populations receiving amiodarone, a signifi-
cant mortality benefit was noted in the patients with ICDs over
the first 3 years of follow-up (206,209). This benefit may
dissipate with follow-up beyond 5 years in some reports (209).
In similar nonrandomized comparisons in sudden death survi-
vors discharged either on electrophysiologically guided antiar-
rhythmic therapy using Class I or III drugs or on an ICD-based
regimen, the survival of the ICD patients was superior, both in
patients with early or advanced LV dysfunction (210). In such
analyses, the use of an ICD in the treatment regimen was the
strongest predictor of long-term survival. ICD recipients also
show improved survival in such comparisons with patients
receiving guided sotalol therapy (266).
Information from randomized trials comparing drug and
device therapy also suggests survival benefits with the ICD in
this population when compared with electrophysiologically
guided drug therapy using Class I agents, propafenone, or
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sotalol (267,268). A large prospective randomized comparative
study comparing ICD therapy with Class III antiarrhythmic
drug therapy, predominantly empiric amiodarone, has been
recently reported (221). In survivors of cardiac arrest and
hemodynamically unstable VT, survival was greater with ICD
therapy. Unadjusted survival estimates for the ICD and drug
therapy were 89.3% versus 82.3%, respectively, at 1 year,
81.6% versus 74.7% at 2 years, and 75.4% versus 64.1% at 3
years. Estimated relative risk reduction with ICD therapy was
39% at 1 year and 31% at 3 years.
Implementation of ICD therapy has been directly com-
pared for safety with antiarrhythmic drug therapy in large
systematic trials. Prospective observational data demonstrate a
low perioperative mortality (0.4% to 1.8%) for primary non-
thoracotomy implants (105,216–218). Similar mortality esti-
mates in large prospective antiarrhythmic drug trials range
from 3.2% to 13.0% (221,240,243). However, these popula-
tions may not be directly comparable. During long-term ther-
apy, drug discontinuation rates have ranged from 7% to 32%,
the lowest being with sotalol in reported data (240). In a large
prospective trial, 98% of randomly assigned patients could be
maintained on ICD therapy, with 25.4% requiring the addition
of drug therapy by 2 years (221). Withdrawal of device therapy
is infrequent and rarely exceeds 2% of implants (216–218).
The addition of an antiarrhythmic drug in selected patients
with ICDs may improve quality of life by reducing arrhythmia
recurrences and the need for shock therapy (266,269).
E. Specific Disease States and Secondary
Prevention of Cardiac Arrest or Sustained
Ventricular Tachycardia
Prior guidelines do not relate the decision to implant an
ICD device to the underlying cardiac disease (270). Recent
information suggests that the underlying disease state may
have an important impact on patient prognosis and will
influence the decision to implant an ICD earlier or later in the
treatment algorithm.
Coronary Artery Disease Patients with coronary artery
disease represent the majority of patients receiving devices in
most reports. Device implantation is widely accepted as im-
proving the outcome of these patients. Patients with reduced
LV function may experience greater benefit with ICD therapy
than with drug therapy (208,210,267). To limit patient risk
during defibrillation efficacy testing (270,271), assessment for
the presence of active ischemia should precede implementa-
tion of device therapy. Furthermore, optimal anti-ischemic
therapy (including, where possible, a b-blocker) will further
enhance survival. Measurement of ventricular function is rec-
ommended, although poor function is not necessarily a con-
traindication to device implantation. Abbreviated defibrillation
threshold testing, however, may be desirable in patients with
elevated pulmonary capillary wedge pressures or severely
compromised cardiac output (271).
Idiopathic Dilated Cardiomyopathy Dilated cardiomyopa-
thy is associated with a high mortality within 2 years of
diagnosis, with a minority of patients surviving 5 years (272).
Approximately one half of these deaths are sudden and
unexpected (273). The combination of poor LV function and
frequent episodes of nonsustained VT in these patients is
associated with an increased risk of sudden death (274).
Moreover, unlike in ischemic heart disease, the value of
electrophysiological studies is limited (275). The efficacy of
drug therapy is low in the presence of impaired LV function
and difficult to predict on the basis of invasive or noninvasive
testing. ICD implantation may be preferred for treatment of
symptomatic VT/VF patients with this condition. In one large
prospective study, this population represented 10% of the
study group and showed survival benefits with ICD rather than
empiric amiodarone therapy similar to the entire study cohort
(221).
Long QT Syndrome The long QT syndromes represent a
spectrum of electrophysiological disorders characterized by a
propensity for development of malignant ventricular arrhyth-
mias, especially polymorphic VT (239,276–278). Because this
is a primary electrical disorder, usually with no evidence of
structural heart disease or LV dysfunction, the long-term
prognosis is excellent if arrhythmia is controlled. Long-term
treatment with b-blockers, permanent pacing, or left cervico-
thoracic sympathectomy is frequently effective (277). ICD
implantation is recommended for selected patients in whom
recurrent syncope, sustained ventricular arrhythmias, or sud-
den cardiac death occur despite drug therapy (276). Further-
more, use of the ICD as primary therapy should be considered
in certain patients, such as those in whom aborted sudden
cardiac death is the initial presentation of the long QT
syndrome, where there is a strong family history of sudden
cardiac death, or when compliance or intolerance to drugs is a
concern (276).
Idiopathic Ventricular Fibrillation It has been estimated
that in 10% of young patients resuscitated from cardiac arrest,
an etiology of VF is not determined despite extensive evalua-
tion (279,280). Electrophysiological testing in these patients
with “idiopathic VF” usually reveals polymorphic VT or VF
that is often suppressible with Class IA drugs (279). However,
the long-term efficacy of drug therapy remains unknown.
Given the guarded prognosis even with effective drug therapy
(the annual rate of sudden cardiac death is estimated to be as
high as 11%), the limited clinical data available appear to
support the use of ICDs in such patients (279–281). Catheter
ablation should be considered before ICD insertion in patients
with idiopathic right or left VT (263).
Hypertrophic Cardiomyopathy Hypertrophic cardiomyop-
athy should be suspected and is often identified as the cause of
sudden death in young athletes (239,282). Ventricular tachy-
arrhythmias are a mechanism of sudden death in this condition
(283). Sudden death may also be the first manifestation of the
disease in a previously asymptomatic individual. Criteria to
risk-stratify these patients are not well defined. In contrast with
other cardiomyopathies, electrophysiological testing may be of
prognostic value because inducible sustained ventricular ar-
rhythmias appear to be associated with cardiac arrest and
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syncope in some studies (284). Studies of patients resuscitated
from cardiac arrest indicate that many patients will experience
another event. Pharmacological therapy in the form of
b-blockers or calcium channel antagonists has frequently been
used, but efficacy in sudden death prevention is not definitively
established. Empiric use of amiodarone has been reported to
be associated with improved survival (282). However, predic-
tion of drug efficacy remains difficult and controversial. Sudden
death survivors should be considered for ICD therapy in
preference to or in conjunction with drug therapy (285).
Because these patients are often young, drug compliance is
frequently an issue. Long-term protection for these patients
may be better afforded by treatment with an ICD.
Arrhythmogenic Right Ventricular Dysplasia Arrhythmo-
genic right ventricular dysplasia can be an important cause of
congestive heart failure and ventricular arrhythmias in some
patients (286). Drug therapy is often used as primary
therapy but is often ineffective. Nonpharmacological op-
tions for treatment of significant arrhythmias include cath-
eter ablation of the sites of tachycardia, surgical disarticu-
lation of the right ventricle, and ICDs. In patients with
drug-refractory malignant arrhythmias, the ICD provides
prophylaxis against syncope due to hemodynamically unsta-
ble VT and sudden death (287,288).
Syncope With Inducible Sustained Ventricular Tachycar-
dia Patients with syncope of undetermined etiology in whom
clinically relevant VT/VF is induced at electrophysiological
study may be candidates for ICD therapy. In these patients, the
induced arrhythmia is presumed to be the cause for syncope
(289–291). Cardiovascular mortality averages 20% annually,
with a large proportion of it sudden. In some patients, antiar-
rhythmic treatment is limited by inefficacy, intolerance, or
noncompliance. ICD therapy is often used with results com-
parable to sustained VT populations (292). In patients with
hemodynamically significant and symptomatic inducible sus-
tained VT, ICD therapy can be a primary treatment option.
F. Pediatric Patients
Pediatric experience with ICDs represents less than 1% of
all implantations (239,293). Special considerations such as the
need for lifelong pharmacological therapy with its associated
problems of noncompliance and side effects make the ICD an
important treatment option for young patients.
Sudden cardiac death is uncommon in childhood but is
associated with three principal forms of cardiovascular disease:
(1) congenital heart disease, (2) cardiomyopathy, and (3)
primary electrical disease (239,294). Patients with preexisting
heart disease are more likely to experience ventricular tachy-
arrhythmias as the immediate cause of sudden death compared
with those with normal hearts (295). However, a lower per-
centage of children undergoing resuscitation survive to hospi-
tal discharge compared with adults (296).
Indications for ICD therapy for pediatric patients are
similar to those for arrhythmias in adults. However, the data
used for risk stratification in adults with coronary artery
disease may have less positive predictive value in pediatric
patients with a variety of underlying diseases (297). Because
the risk of unexpected sudden death may be greatest in young
patients with diseases such as hypertrophic cardiomyopathy or
long QT syndrome, a family history of sudden death may
influence the decision to use an ICD in a pediatric patient
(277,282).
In patients with congenital heart disease, sudden death has
been estimated to occur in 1.5% to 2.5% of patients per decade
after repair of tetralogy of Fallot (298). An even higher risk has
been identified for patients with transposition of the great
arteries and aortic stenosis, with most cases presumed to be
due to a malignant ventricular arrhythmia associated with
ischemia, ventricular dysfunction, or a rapid response to atrial
flutter (120,299). An ischemic substrate for arrhythmias lead-
ing to sudden cardiac death also exists in congenital coronary
anomalies or after Kawasaki disease.
ICD therapy may be preferable to antiarrhythmic drugs in
patients with dilated cardiomyopathy or other causes of im-
paired ventricular function who experience sustained ventric-
ular arrhythmias because of concern about drug-induced
proarrhythmia and myocardial depression. ICDs may also be
considered as a bridge to orthotopic heart transplantation in
pediatric patients with ventricular arrhythmias whose anoma-
lies are not amenable to surgical correction, particularly given
the longer times to donor procurement in younger patients
(300). Young patients with hypertrophic cardiomyopathy have
a higher annual sudden cardiac death event rate than adults
(282,301). A limited experience with ICDs implanted in this
population after resuscitation has been encouraging (285,
293,302).
G. Primary Prevention of Sudden Cardiac Death
Coronary Artery Disease Nonsustained VT in patients with
prior MI and LV dysfunction is associated with a 2-year
mortality estimated at 30% (303,304). Approximately one half
of this is believed to be arrhythmic in origin. Antiarrhythmic
drug therapy has been widely prescribed in patients after MI
with and without ventricular arrhythmia, but evidence of
improved survival with this approach is not forthcoming.
Increased mortality in coronary disease patients with and
without nonsustained VT has actually been noted with specific
Class I agents (305). Empiric amiodarone therapy has shown
inconsistent survival benefit in large prospective randomized
trials (250,251), although quantitative overviews (meta-
analyses) suggest total mortality may be reduced compared
with other medical therapies (241,306). In this population
electrophysiological testing has identified a subgroup with
inducible sustained ventricular tachyarrhythmias that is at high
risk for sudden death (307). While arrhythmia-related symp-
toms and repeated MIs may help identify such patients,
asymptomatic persons post MI may also be at high risk
(304,307,308). Survival of patients treated with drugs that
suppressed induced arrhythmias improved in comparison with
historically untreated or drug-refractory patients (307). In a
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recent prospective randomized trial, improved survival was
documented after implantation of ICDs in patients with induc-
ible and nonsuppressible ventricular tachyarrhythmias when
compared with conventional drug therapy, including amioda-
rone (220).
After Coronary Artery Bypass Surgery Routine ICD inser-
tion does not improve survival in patients with coronary artery
disease undergoing bypass surgery who are believed to be at
high risk of sudden death based on QRS duration and severe
LV dysfunction. In one randomized study, no benefit was noted
over placebo (309) in patients with ejection fractions ,35%
and a positive signal-averaged ECG.
As a Bridge to Heart Transplantation Orthotopic heart
transplantation has emerged as an acceptable therapeutic
alternative for selected patients with congestive heart failure
caused by severe ventricular dysfunction. About 20% of pa-
tients requiring transplantation die awaiting a donor organ,
with a significant incidence of sudden death. ICDs effectively
prevent sudden death in these patients (310,311). This benefit
is diluted by mortality due to heart failure in some patients
(310–312).
Other Populations Other high-risk populations under
study for similar benefits include asymptomatic patients with
dilated cardiomyopathy and ventricular dysfunction or symp-
tomatic congestive heart failure (313–315), but no recommen-
dations can yet be made with respect to these patients.
H. Contraindications to ICD Therapy
ICD therapy is not recommended for the conditions listed
below. The first major group, which can be identified by
invasive and noninvasive preimplantation testing, includes
those patients in whom a reversible triggering factor for
VT/VF can be identified, such as ventricular tachyarrhythmias
in evolving AMI or electrolyte abnormalities. Another popu-
lation is coronary disease patients without inducible or spon-
taneous VT undergoing routine coronary bypass surgery (309).
Similarly, patients with Wolff-Parkinson-White syndrome pre-
senting with VF secondary to atrial fibrillation should undergo
catheter or surgical ablation if their accessory pathways are
amenable to such treatment.
Patients with terminal illnesses, NYHA Class IV drug-
refractory congestive heart failure who are not candidates for
cardiac transplantation, or with a life expectancy not exceeding
6 months are likely to obtain limited benefit from ICD therapy.
Significant behavioral disorders, including anxiety, device de-
pendence, or social withdrawal have been described (316,317).
A history of psychiatric disorders, including uncontrolled de-
pression and substance abuse that interfere with the meticu-
lous care and follow-up needed by these patients, is a relative
contraindication to device therapy.
Patients who have frequent tachyarrhythmias that may
trigger shock therapy, such as sustained VT not responsive to
antitachycardia pacing or pharmacological therapy, are not
suitable candidates for a device because these events would
cause frequent device activation and multiple shocks. Alterna-
tive therapies, such as combining drugs or ablation with ICD
insertion, should be considered.
I. Cost-Effectiveness of ICD Therapy
Several studies have addressed the cost-effectiveness of
ICD therapy. The cost-effectiveness ratio compares the total
cost of ICD therapy with the total cost of an alternative
management strategy such as amiodarone or guided serial drug
testing. The overall costs of the ICD have been reduced as the
result of nonthoracotomy implantation methods and improve-
ments in ICD reliability and longevity that reduce cost of
device replacement and modification. Significant reductions in
initial costs have been realized, with newer treatment algo-
rithms eliminating prolonged drug testing (318,319).
The early studies of ICD cost-effectiveness were based on
mathematical models and relied on nonrandomized studies to
estimate clinical efficacy and cost. These studies found cost-
effectiveness ratios of $17,000 (320), $18,100 (321), and
$29,200 per year of life saved (322). A more recent model
incorporated costs of nonthoracotomy ICDs and efficacy esti-
mates based on randomized trials and found ICD cost-
effectiveness was between $27,300 and $54,000 per life-year
gained, corresponding to risk reduction of 40% and 20%,
respectively (323).
Several recently completed and ongoing randomized clinical
trials have measured cost as well as clinical outcomes and thus
can directly estimate ICD cost-effectiveness. A preliminary
analysis of the MADIT (324) trial found the ICD to have a
cost-effectiveness ratio of $27,000 per life-year gained. All
studies suggest that ICD implantation in appropriately selected
patients has a cost-effectiveness ratio comparable to other
cardiovascular therapies as well as widely accepted noncardiac
therapies such as renal dialysis ($30,000 to $50,000 per year of
life saved). The cost-effectiveness of the ICD is more favorable
in patients with high risk of arrhythmic death but low risk of
other causes of death. Cost-effectiveness of the ICD would be
improved by lowering the cost of the device itself and further
improving its reliability and longevity.
J. Selection of ICD Generators
All ICDs currently marketed in the United States incorpo-
rate a number of advanced features, including multiple tachy-
cardia zones, with rate detection criteria and tiered therapy
(including low-energy cardioversion and high-energy defibril-
lation shocks) independently programmable for each zone.
Furthermore, all devices incorporate programmable ventricu-
lar demand pacing and extensive diagnostics, including stored
electrograms of rhythms immediately before and after tachy-
cardia detection and therapy. The principal feature distin-
guishing some ICDs from others is the availability of antitachy-
cardia pacing as a programmable therapy option. The addition
of antitachycardia pacing increases the cost of the device by
5% to 10% compared with similar ICDs without this feature.
The vast majority of devices used for new implants are small
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enough for pectoral implants. Larger devices suitable for
abdominal implants are available primarily as replacement
generators in patients with preexisting lead systems; these
larger devices are available at a cost savings of approximately
10% to 25% compared with the smaller devices.
Antitachycardia pacing appears to be a useful feature in the
majority of patients receiving ICDs. In one study (325),
antitachycardia pacing was activated in 68% of patients receiv-
ing ICDs with such a capability, despite the fact that the
efficacy of antitachycardia pacing was tested with the device in
only 53% of the patients in whom it was activated; in the
remainder, antitachycardia pacing algorithms were pro-
grammed empirically. In the patients with activated antitachy-
cardia pacing, 96% of all detected episodes of ventricular
tachyarrhythmias were terminated with pacing (325). Acceler-
ation of VT by antitachycardia pacing remains a concern, with
most series reporting an incidence of antitachycardia pacing
acceleration of an episode of VT ranging from 3% to 6%
(326). Patients whose only clinical arrhythmia detected
before ICD implantation was VF have a lower likelihood of
having VT subsequently detected by the ICD than do
patients with a prior history of VT (327). However, the
incidence of subsequent VT in those with a history of only
VF before device implantation is not inconsiderable (18%
during 14 months of follow-up in one study [327]), so it is
reasonable to select a device with antitachycardia pacing
even in such patients.
Defibrillators incorporating an atrial lead have recently
become available. Such devices not only provide dual-chamber
pacing but also use the pattern of sensed atrial depolarization
to distinguish supraventricular from ventricular arrhythmias. A
dual-chamber pacemaker–ventricular defibrillator device is an
appropriate choice for an ICD candidate who has a concomi-
tant need for dual-chamber pacing or a patient with supraven-
tricular tachycardia thought likely to lead to inappropriate ICD
therapies.
K. ICD Follow-up Program
All patients with ICDs require periodic and meticulous
follow-up to ensure safety and optimal device performance.
The goals of ICD follow-up include monitoring of device
system function; optimizing performance for maximal clinical
effectiveness and system longevity; minimizing complications;
anticipating replacement of system components; ensuring
timely intervention for clinical problems; patient tracking,
education, and support; and maintenance of ICD system
records. The need for device surveillance and management
should be discussed a priori with patients before insertion of an
ICD. Compliance with device follow-up is an important ele-
ment in evaluating appropriate candidates for device therapy
and obtaining the best long-term result. ICD follow-up is best
achieved in an organized program analogous to pacemaker
follow-up at outpatient clinics (198).
Institutions performing implantation of these devices
should also maintain these facilities for inpatient and outpa-
tient use. Such facilities should obtain and maintain implanta-
tion and follow-up support devices for all ICDs used at that
facility. The facility should be staffed or supported by a fully
trained clinical cardiac electrophysiologist (328) who may work
in conjunction with trained associated professionals
(198,328,329). Access to these services should be available as
far as is feasible on both a regularly scheduled and emergent
24-hour-per-day basis. The implantation and/or follow-up fa-
cility should be able to locate and track patients who have
received ICDs or who have entered the follow-up program.
Elements of ICD Follow-up The follow-up of an ICD
patient must be individualized in accordance with the patient’s
clinical status and conducted by a fully trained clinical cardiac
electrophysiologist. In general, device programming is initiated
at implantation and should be reviewed at predischarge and/or
subsequent postoperative electrophysiological testing. Devices
should be followed at 1- to 4-month intervals, depending on
the device model and the patient’s clinical status. Manufactur-
ers’ guidelines for device follow-up vary with individual models
and should be available. Transtelephonic follow-up should
always be supplemented by clinic visits at a minimum of
3-month intervals for patient and device evaluation (330).
It is often necessary to reprogram the initially selected
parameters either in the outpatient clinic or by electrophysio-
logical testing. When device function or concomitant antiar-
rhythmic therapy is modified, electrophysiological testing can
be and often is required to evaluate sensing, pacing, or
defibrillation functions of the device. Particular attention
should be given to review of sensing parameters, programmed
defibrillation and pacing therapies, device activation, and event
logs. Technical elements requiring review include battery
status, lead system parameters, and elective replacement indi-
cators. Intervening evaluation of device function is often
necessary. In general, in patients experiencing device activa-
tion, with or without therapy, delivery should be evaluated
shortly after the event until a regular acceptable pattern of
patient symptomatology and tolerance for such events is
established and device behavior is deemed reliable, safe, and
effective.
After insertion of a device, its performance should be
reviewed, limitations on the patient’s specific physical activities
established, and registration accomplished. Recent policies on
driving advise the patient with an ICD to avoid operating a
motor vehicle for a minimum of 3 months and preferably 6
months after the last symptomatic arrhythmic event to deter-
mine the pattern of recurrent VT/VF (331,332). Interactions
with electromagnetic interference sources, impact on employ-
ment, and prophylaxis for device infections should be dis-
cussed. ICD recipients should be encouraged to carry proper
identification and information about their device at all times.
Patients receiving these devices can experience transient or
sustained emotional disturbances. Education and psychologi-
cal support before, during, and after ICD insertion are highly
desirable and can improve the patient’s quality of life
(316,317).
1198 GREGORATOS ET AL. JACC Vol. 31, No. 5
PACEMAKER IMPLANTATION GUIDELINES April 1998:1175–209
Indications for ICD Therapy
Class I
1. Cardiac arrest due to VF or VT not due to a transient or
reversible cause. (Level of evidence: A) (103–105,202,203,
205–211,216,217,219,221,238,260,267,269)
2. Spontaneous sustained VT. (Level of evidence: B) (103–
105,202,203,205–211,216,217,219)
3. Syncope of undetermined origin with clinically relevant,
hemodynamically significant sustained VT or VF in-
duced at electrophysiological study when drug therapy
is ineffective, not tolerated, or not preferred. (Level of
evidence: B) (204,213,215,219,227,228,266)
4. Nonsustained VT with coronary disease, prior MI, LV
dysfunction, and inducible VF or sustained VT at
electrophysiological study that is not suppressible by a





1. Cardiac arrest presumed to be due to VF when electro-
physiological testing is precluded by other medical
conditions. (Level of evidence: C) (211,218,267,276)
2. Severe symptoms attributable to sustained ventricular
tachyarrhythmias while awaiting cardiac transplanta-
tion. (Level of evidence: C) (310,311)
3. Familial or inherited conditions with a high risk for
life-threatening ventricular tachyarrhythmias such as
long QT syndrome or hypertrophic cardiomyopathy.
(Level of evidence: B) (8,41,277,282,284,288,300–302)
4. Nonsustained VT with coronary artery disease, prior
MI, and LV dysfunction, and inducible sustained VT or
VF at electrophysiological study. (Level of evidence: B)
(103,205,212,217,220,307,308)
5. Recurrent syncope of undetermined etiology in the
presence of ventricular dysfunction and inducible ven-
tricular arrhythmias at electrophysiological study when
other causes of syncope have been excluded. (Level of
evidence: C)
Class III
1. Syncope of undetermined cause in a patient without
inducible ventricular tachyarrhythmias. (Level of evi-
dence: C)
2. Incessant VT or VF. (Level of evidence: C)
3. VF or VT resulting from arrhythmias amenable to
surgical or catheter ablation; for example, atrial ar-
rhythmias associated with the Wolff-Parkinson-White
syndrome, right ventricular outflow tract VT, idiopathic
left ventricular tachycardia, or fascicular VT. (Level of
evidence: C)(259–263)
4. Ventricular tachyarrhythmias due to a transient or
reversible disorder (eg, AMI, electrolyte imbalance,
drugs, trauma). (Level of evidence: C) (333)
5. Significant psychiatric illnesses that may be aggravated
by device implantation or may preclude systematic
follow-up. (Level of evidence: C) (316,317)
6. Terminal illnesses with projected life expectancy <6
months. (Level of evidence: C)
7. Patients with coronary artery disease with LV dysfunc-
tion and prolonged QRS duration in the absence of
spontaneous or inducible sustained or nonsustained VT
who are undergoing coronary bypass surgery. (Level of
evidence: B) (309)
8. NYHA Class IV drug-refractory congestive heart failure
in patients who are not candidates for cardiac trans-
plantation. (Level of evidence: C)
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cardioverter-defibrillator for, 1196
Ventricular fibrillation, 1183, 1199
implantable cardioverter-defibrillator for, 1193




single-lead, atrial sensing, 1188t
in sinus node dysfunction, 1191
Ventricular rate, pauses in, 1186
Ventricular tachycardia (VT), 1197, 1199
implantable cardioverter-defibrillator for, 1105–
1196, 1193
alternatives to, 1194
comparison with drug therapy, 1194–1195
for syncope with, 1196
after myocardial infarction, 1196
prevention and termination of, by pacing, 1182,
1183
VVI pacing, in idiopathic dilated cardiomyopathy,
1187
VVIR pacing, 1190, 1191
in sinus node dysfunction, 1191
W
Wolff-Parkinson-White syndrome, 1197
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